WO1996022529A1 - A method of generating a plurality of chemical compounds in a spatially arranged array - Google Patents

A method of generating a plurality of chemical compounds in a spatially arranged array Download PDF

Info

Publication number
WO1996022529A1
WO1996022529A1 PCT/US1996/001005 US9601005W WO9622529A1 WO 1996022529 A1 WO1996022529 A1 WO 1996022529A1 US 9601005 W US9601005 W US 9601005W WO 9622529 A1 WO9622529 A1 WO 9622529A1
Authority
WO
WIPO (PCT)
Prior art keywords
array
compounds
reaction site
chemical
molecular
Prior art date
Application number
PCT/US1996/001005
Other languages
French (fr)
Inventor
Robert A. Zambias
David A. Bolten
Joseph C. Hogan
Paul Furth
David S. Casebier
Cheng Tu
Original Assignee
Arqule, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arqule, Inc. filed Critical Arqule, Inc.
Priority to PL96327437A priority Critical patent/PL327437A1/en
Priority to NZ301594A priority patent/NZ301594A/en
Priority to JP8522446A priority patent/JPH11503720A/en
Priority to EP96902775A priority patent/EP0804726A4/en
Priority to AU47059/96A priority patent/AU719584C/en
Publication of WO1996022529A1 publication Critical patent/WO1996022529A1/en
Priority to NO973335A priority patent/NO973335L/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • CCHEMISTRY; METALLURGY
    • C40COMBINATORIAL TECHNOLOGY
    • C40BCOMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B50/00Methods of creating libraries, e.g. combinatorial synthesis
    • C40B50/08Liquid phase synthesis, i.e. wherein all library building blocks are in liquid phase or in solution during library creation; Particular methods of cleavage from the liquid support
    • CCHEMISTRY; METALLURGY
    • C40COMBINATORIAL TECHNOLOGY
    • C40BCOMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00Methods of screening libraries
    • C40B30/04Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/551Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being inorganic
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/70Nanostructure
    • Y10S977/773Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y10S977/774Exhibiting three-dimensional carrier confinement, e.g. quantum dots
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/70Nanostructure
    • Y10S977/778Nanostructure within specified host or matrix material, e.g. nanocomposite films
    • Y10S977/779Possessing nanosized particles, powders, flakes, or clusters other than simple atomic impurity doping
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/70Nanostructure
    • Y10S977/788Of specified organic or carbon-based composition
    • Y10S977/789Of specified organic or carbon-based composition in array format
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/70Nanostructure
    • Y10S977/788Of specified organic or carbon-based composition
    • Y10S977/789Of specified organic or carbon-based composition in array format
    • Y10S977/79Of specified organic or carbon-based composition in array format with heterogeneous nanostructures
    • Y10S977/791Molecular array

Definitions

  • nucleotides can form complementary base pairs so that
  • a biologically active molecule referred to as a ligand
  • binds with another molecule usually a macromolecule referred to as ligand-acceptor (e.g. a receptor or an
  • a currently favored strategy for development of agents which can be used to treat diseases involves the discovery of forms of ligands of biological receptors, enzymes, or related macromolecules, which mimic such ligands and either boost (i.e., agonize) or suppress (i.e., antagonize) the activity of the ligand.
  • boost i.e., agonize
  • suppress i.e., antagonize
  • the discovery of such desirable ligand forms has traditionally been carried out either by random screening of molecules (produced through chemical synthesis or isolated from natural source's, for example, see K. Nakanishi, Acta Pharm.
  • peptides as drugs are not favored as drugs.
  • An additional limitation of small peptides as drugs is their low affinity for ligand acceptors. This phenomenon is in sharp contrast to the affinity demonstrated by large, folded polypeptides, e.g., proteins, for specific acceptors, e.g., receptors or enzymes, which can be in the subnanomolar range.
  • peptides to become effective drugs they must be transformed into nonpeptidic organic structures, i.e., peptide mimetics, which bind tightly, preferably in the nanomolar range, and can withstand the chemical and
  • peptidomimetics in the majority of cases the results in one biochemical area e.g., peptidase inhibitor design using the enzyme substrate as a lead, cannot be transferred for use in another area, e.g., tyrosine-kinase inhibitor design using the kinase substrate as a lead.
  • peptides which also comprise alpha-amino acids
  • nonpeptide scaffolds such as
  • V. D. Huebner and D.V. Santi U.S. Patent No. 5,182,366
  • peptides were produced in uniform amounts which were then separately screened for a biological activity of interest.
  • affinity chromatography This type of separation is appropriately called “affinity chromatography” and remains an extremely effective and widely used separation technique (see Perry, E. S. in Techniques of Chemistry, Vol. 12 (J. Wiley) & May, S. W. in Separations and Purification 1978, 3rd ed.). It is certainly much more selective than traditional chromatographic techniques, e.g chromatography on silica, alumina, silica or alumina coated with long-chain hydrocarbons, polysaccharide and other types of beads or gels which in order to attain their maximum separating efficiency need to be used under conditions that are damaging to
  • biomolecules e.g., conditions involving high pressure, use of organic solvents and other denaturing agents, etc. (for example see Stewart, D. J., et al. J. Biotechnology 1989, 22, 253-266; Brown, E., et al. Int. Symp. Affinity.
  • 5,340,474 has developed a chromatographic method to obtain ligands which have the required affinity specific for a selected member of an array of analytes by providing maximal diversity in the choice of these ligands.
  • a key to this technology is the use of a flow-through 96-well plate
  • Protein is then loaded onto each column in the sorbent plate, and the proteins that are bound to the chromatographic sorbents are eluted, then collected into a second pretreated microplate (Benedek, K. et al. J. Chromatography 1992, 627, 51-61).
  • Sets of paralogs are constructed by systematically varying five independent parameters drawn from protein structure literature: 1. a hydrophobic index; 2. an
  • This invention discloses a system for the design, synthesis and use of logically arranged collections of synthetic product molecules called "molecular constructs" from structural elements in such a manner that the collection of molecular constructs possesses a constant structural element and a variable structural element.
  • the definitions are shown below.
  • a "construct” is a molecule which is a member of a collection of molecules containing a common constant
  • An "array” is a logical positional ordering of molecular constructs in Cartesian coordinates.
  • a “bond” or “chemical bond” is used to describe a group of electrons that is shared between two atoms. This term also denotes an ionic, covalent or other attractive force between two atoms.
  • a "building block” is any molecule useful in the
  • fragment or "structural diversity element” refer to the common variable structural element of a
  • the "molecular core” is the common constant structural element of a molecular construct.
  • a "spatial address” is a position in the array defined by unique Cartesian coordinates.
  • a "sub-array” is a set of spatial addresses within a given array containing those molecular constructs having a common molecular core and differ from each other by 0 (zero) or 1 (one) change in a fragment.
  • a “relative address” refers to a location within the array or sub array comparable to any selected address, and differing by 0 (zero) or only 1 (one) change in the common variable structural element.
  • An “operator” is a simultaneous and/or concurrent change in the condition of at least two spatial addresses in
  • an operator in terms of this invention can be the reaction of at least one site on the molecular core capable of becoming or providing
  • spectroscopic inhibition assays disc assays and binding affinity assays; mechanical motions or manipulations; passage of time which includes resting & evaporation; heating and cooling; iteration of previous steps in a synthesis;
  • This invention is directed to an m ⁇ n array of
  • each of said compounds has at least one structural diversity elements chosen from the group consisting of:
  • scaffold structure is selected from the group consisting of:
  • This invention is still further directed to an m ⁇ n array of different chemical compounds wherein each of said compounds has at least one of the structural diversity elements defined herein and wherein the scaffold structure may be a chemical molecule having at least three carbon atoms and at least two sites on the molecule capable of undergoing a reaction to change the structure, usually by the addition of other- molecules to a site capable of reacting to form or attach a structural diversity element.
  • This invention is still yet further directed to an n ⁇ m array of chemical compounds called molecular constructs possessing a logical ordering of molecular constructs
  • each sub array is comprised of
  • each sub array within the array is related to all other sub arrays in that all corresponding molecular constructs within each sub array has at least one change in the structural diversity
  • n, m, k and 1 are all integers greater than 1.
  • the specific integers used for m and n are not critical and any can be selected depending upon the desired form of the array.
  • the above defined array of chemical compounds is also directed to arrays wherein m multiplied by n is greater than 10, greater than 20, greater than 100, greater than 200, greater than 500, greater than 1000 or even greater than 5000. Again, the final number can be any multiple of the selected m and n values.
  • each sub array is comprised of a) at least K.l molecular constructs having a common molecular core and differing from other k.l molecular constructs in the sub array by at least one change in the structural diversity element attached to the molecular core;
  • each sub array within the array is related to all other sub arrays in that all corresponding molecular constructs with each sub array has at least one change in the structural diversity elements;
  • each molecular construct is equidistant from at least two of its neighboring molecular constructs.
  • a preferred array is that defined immediately above wherein when n and m are greater than 3 and the chemical compounds are surrounded on four sides by four equidistant neighboring other chemical compounds.
  • the present invention covers n ⁇ m arrays of chemical compounds called molecular constructs possessing a logical ordering of molecular constructs comprising at least one k ⁇ l sub array within the array wherein each sub array is comprised of
  • each sub array within the array is related to all other sub arrays in that all corresponding molecular constructs within each sub array has at least one change in the structural diversity elements;
  • each molecular construct is separated from all other molecular constructs by a container material.
  • the contained materials for the above cited array may employ glass, polymers, silicon, or any other material known by those of ordinary skill in the art.
  • the present invention is directed to an n ⁇ m ⁇ q array of chemical compounds called molecular constructs possessing a logical ordering of molecular constructs
  • each sub array is comprised of
  • each sub array within the array is related to all other sub arrays in that all corresponding molecular constructs within each sub array has at least one change in the structural diversity elements;
  • the present invention is directed to an n ⁇ m ⁇ q array wherein the function is the addition of an organic structure selected from the group consisting of an amine, an aldehyde, an alcohol, a ketone, a carboxylic acids, an ether and an epoxy, and wherein the function may or may not be an analytic technique.
  • Figure 1 is a graphical representation of an array vertex illustrating the relationship between the building blocks, their addresses and the various operators therefor;
  • Figure 2 is a schematic diagram representing the
  • This invention pertains to the logical layout
  • arrays of chemical compound for one of a variety of applications, in which the desired properties of the compound can be measured and correlated to specific ordered changes in the fragments use to construct them.
  • the array is ordered in such a fashion as to expedite assembly, to maximize the informational content derived from the testing and to facilitate the rapid extraction of that data from the testing process. This method has great utility in accelerating the development of compounds have the optimal properties for the desired application.
  • the arrays are constructed from logically ordered and arranged sub-arrays of compounds.
  • Each sub-array consists of spatially addressable sets of structurally related individual chemical compounds, ranging in number from one to 10 12 and possessing the following properties: (1) a. common structural scaffold element referred to as a "molecular core" and (2) a variable structural diversity element referred to as a fragment, in such a manner that the variation between any two compounds within a given sub-array consists only of either zero (0) or one (l) change in a fragment.
  • These arrays may in turn be arranged in such a manner to form higher order arrays consisting of sets of arrays and tested to provide information regarding the optimum structural features available for the application.
  • the sub-arrays are arranged in such a manner that the direct comparisons of compounds automatically yields
  • An application of this invention is the rapid
  • These arrays may be assembled to form a "super array” for exhaustive testing. This approach provides a large scale view over different structures, functionalities and spatial arrangements for exploring biological activity.
  • the physical construction of the array also permits the logical and rapid analysis of synthetic results for the assurance of purity and quality. By testing a series of loci within any given sub-array, it becomes possible to determine the efficacy of construction of that core, and eliminate those fragments (i.e., process development within the
  • a further application of this invention pertains to the ability to construct materials in a modular fashion, so as to facilitate their selection for such properties as strength, stability, reactivity or any other desired physical property. Whereas many methods rely upon logical choice for fragment candidates in such efforts, this method provides for the construction and testing of all candidates, thereby eliminating any compromises which
  • the invention provides for the development of seamless technology between planning, logistical
  • the invention provides for the integrated design and delivery of a unified chemical discovery system, which by application of logic and implementation of information management, has been heretofore unknown.
  • the invention provides for the occupation of all possible spatial addresses and therefore allows for complete analysis of desired properties. This concept can be extended toward the design and manufacture of appropriate hardware and software to support the integrated aspect of this modular construction.
  • the logically arranged arrays of the present invention are fundamentally different from all known prior art.
  • These arrays may be constructed from a wide variety of molecular cores, several examples of whi :h are shown below.
  • the criteria for core candidates are that the scaffold a) present attachment points for at least two structural diversity elements; b) is able to present these structural diversity elements in controlled, varying spatial
  • the molecular cores are linear, branched or cyclic organic compounds.
  • the molecular cores comprise a chemical molecule having at least three carbon atoms and at least two sites on the molecule capable of undergoing a reaction to change the structure, usually by the addition of other molecules to a site capable of reacting to form or attach a structural diversity element.
  • a molecular core is an aminimide
  • These compounds may be synthesized in a number of ways, from the reaction of an epoxide, an ester, and a hydrazine, as well as alkylation of a hydrazide, as shown below.
  • a scaffold capable of forming a molecular core of an oxazolone molecule.
  • Methylidene amides are formed from the sequential reaction of aldehydes, then amines with oxazolones. These compounds and their congeners may be in turn transformed into imidazolones:
  • Sulfonylaminimides and phosphonylaminimides are still further examples of molecular cores which can be constructed in an analogous manner as their carbon-based counterparts, with the exception of sulfonate esters not participating in the reaction of an epoxide and hydrazine in the desired manner.
  • aminimide oxazolone
  • sulphonylaminimide sulphonylaminimide
  • phosphonylaminimide phosphonylaminimide
  • imidazopyrazinones oxazolopyridines, pyrroles, pyrrolidines, imidazolidones, quinolones, amino acids, macrolides, penems, saccharides, xanthins, benzothiadiazine, anthracyclines, dibenzocycloheptadienes, inositols, porphyrins, corrins, and carboskeletons presenting geometric solids (e.g.,
  • the structural diversity elements may be the same or different, may be of a variety of structures and may differ markedly in their physical or functional properties, or may be the same; they may also be chiral or symmetric or from a compound which is chiral or symmetric.
  • the structural diversity elements are preferably selected from:
  • Polypeptides (n 31 - 70), such as big endothelin,
  • Nucleotide probes (n 2 - 25) and oligonucleotides (n > 25) including all of the various possible; homo and hetero-synthetic combinations and
  • motif is defined as an organic molecule having or containing a specific structure that has biological activity, such as a molecule having a
  • This term includes any of the well known basic structures of pharmaceutical compounds including
  • beta-lactams such as penicillin, known to inhibit bacterial cell wall biosynthesis
  • dibenzazepines known to bind to CNS receptors and used as antidepressants
  • polyketide macrolides known to bind to bacterial ribosymes, etc.
  • a reporter element such as a natural or synthetic dye or a residue capable of photographic amplification which possesses reactive groups that may be synthetically
  • Preferred reactive groups are amino, thio, hydroxy, carboxylic acid, carboxylic acid ester, particularly methyl ester, acid chloride, isocyanate alkyl halides, aryl halides and oxirane groups.
  • Suitable groups include vinyl groups, oxirane groups,
  • a macromolecular component such as a macromolecular surface or structures which may be attached to the
  • macromolecular components include porous and non-porous inorganic components, such as, for example, silica, alumina, zirconia, titania and the like, as commonly used for various applications, such as normal and reverse phase chromatographic separations, water purification, pigments for paints, etc.; porous and non-porous organic macromolecular components, including synthetic components such as
  • styrenedivinyl benzene beads various methacrylate beads, PVA beads, and the like, commonly used for protein purification, water softening; and a variety of other applications, natural components such as native and functionalized celluloses, such as, for example, agarose and chitin, sheet and hollow fiber membranes made from nylon, polyether sulfone or any of the materials mentioned above.
  • the molecular weight of these macromolecules may range from about 1000 Daltons to as high as possible.
  • nano-particles 1000 - 5000 Angstroms
  • membranes gels, macroscopic surfaces or
  • Structural diversity elements may also be a chemical bond to a suitable organic moiety, a hydrogen atom, an organic moiety which contains a suitable electrophilic group, such as an aldehyde, ester, alkyl halide, ketone, nitrile, epoxide or the like; a suitable nucleophilic group, such as a hydroxyl, amino, carboxylate, amide, carbanion, urea or the like; or one of the other structural diversity elements defined below.
  • structural diversity elements may join to form a ring, bi-cyclic or tri-cyclic ring system; or structure which connects to the ends of the repeating unit of the compound defined by the preceding formula; or may be separately connected to other moieties.
  • Structural diversity elements on a scaffold may be the same or different and each may be one or more atoms of carbon, nitrogen, sulfur, oxygen, any other inorganic
  • the structural diversity elements may be cyano, nitro, halogen, oxygen, hydroxy, alkoxy, thio, straight or branched chain alkyl, carbocyclic aryl and substituted or heterocyclic derivatives thereof.
  • Structural diversity elements may be different in adjacent molecular cores and have a selected stereochemical
  • linear chain or branched chained alkyl groups means any substituted or unsubstituted acyclic carbon-containing compounds, including alkanes, alkenes and alkynes.
  • Alkyl groups having up to 30 carbon atoms are preferred.
  • alkyl groups include lower alkyl, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl; upper alkyl, for example, octyl, nonyl, decyl, and the like; lower alkylene, for example, ethylene, propylene, propyldiene, butylene,
  • alkenyl such as 1-decene, 1-nonene, 2,6-dimethyl-5-octenyl, 6-ethyl-5-octenyl or beptenyl, and the like
  • alkynyl such as 1-ethynyl, 2-butynyl, 1-pentynyl and the like.
  • alkynyl such as 1-ethynyl, 2-butynyl, 1-pentynyl and the like.
  • alkyl group may also contain various substituents in which one or more hydrogen atoms has been replaced by a functional group.
  • Functional groups include but are not limited to hydroxyl, amino, carboxyl, amide, ester, ether, and halogen (fluorine, chlorine, bromine and iodine), to mention but a few.
  • Specific substituted alkyl groups can be, for example, alkoxy such as methoxy, ethoxy, butoxy, pentoxy and the like, polyhydroxy such as 1,2-dihydroxypropyl, 1,4-dihydroxy-1-butyl, and the like;
  • substituted and unsubstituted carbocyclic groups of up to about 20 carbon atoms means cyclic carbon-containing compounds, including but not limited to cyclopentyl, cyclohexyl, cycloheptyl, adamantyl, and the like. Such cyclic groups may also contain various
  • substituents in which one or more hydrogen atoms has been replaced by a functional group include those described above, and lower alkyl groups as described above.
  • the cyclic groups of the invention may further comprise a heteroatom.
  • structural diversity element A is cyclohexanol.
  • substituted and unsubstituted aryl groups means a hydrocarbon ring bearing a system of
  • conjugated double bonds usually comprising (4p - 2) pi bond electrons, where p is an integer equal to or greater than 1.
  • aryl groups include, but are not limited to, phenyl, naphthyl, anisyl, toluyl, xylenyl and the like.
  • aryl also includes aryloxy, aralkyl, aralkyloxy and heteroaryl groups, e.g., pyrimidine, morpholine, piperazine, piperidine, benzoic acid, toluene or thiophene and the like.
  • aryl groups may also be substituted with any number of a variety of
  • functional groups on the aryl groups can be nitro groups.
  • structural diversity elements can also represent any combination of alkyl, carbocyclic or aryl groups; for example, 1-cyclohexylpropyl,
  • the structural diversity element may also be a
  • connecting group that includes a terminal carbon atom for attachment to the quaternary nitrogen and may be different in v djacent n units.
  • At least one of the structural diversity elements represents an organic or inorganic macromolecular surface.
  • preferred macromolecular surfaces include ceramics such as silica and alumina, porous and non-porous beads, polymers such as a latex in the form of beads, membranes, gels, macroscopic surfaces or coated versions or composites or hybrids thereof.
  • a 10,240-component array is synthesized according to the teaching of the invention, from eight oxazolones (Building Block A), 32 aldehydes (Building Block B), and 40 amines (Building Block C).
  • AN 1001 Protocol Tetrahydrofuran (THF) solutions of the building blocks are prepared according to the protocols generated on the spread sheets entitled "AN 1001 SOLUTION PROTOCOLS. CALCULATIONS, AND BUILDING BLOCK SELECTION".
  • the Building Block solutions are 250 mM in “A”, 250 mM in “B”, and 500 mM in “C”.
  • a reaction plate contains 80 spatial addresses each (8 X 10) and a row
  • the initial cycle's first operator is spatial delivery of 200 ⁇ l (1 eq., 50 ⁇ moles) of the "A" building block solution according to the spread sheet entitled "AN 1001 SPATIAL LAYOUT, "A" BUILDING
  • the operator is spatial delivery of 200 ⁇ l (1 eq., 50 ⁇ moles) of the "B" Building Blocks to the same reaction plates according to the spread sheet entitled “AN 1001 SPATIAL LAYOUT, "B” BUILDING BLOCKS.”
  • the third operator is addition to the same reaction plates of 50 ⁇ L of a I M (1 eq., 50 ⁇ moles) solution of triethylamine in THF to all the spatial addresses that "A" and "B” building Blocks were added.
  • the forth operator is placement of the reaction blocks on an agitator at 60 degrees centigrade for 1.5 hrs.
  • the fifth operator is spatial addition of 100 ⁇ l (1 eq., 50 ⁇ moles) of the "C” building, block solutions according to the spread sheet entitled “AN 1001 SPATIAL LAYOUT, "C” BUILDING BLOCKS.”
  • the sixth operator is spatial addition of 100 ⁇ l (1 eq., 50 ⁇ moles) of the "C” building, block solutions according to the spread sheet entitled “AN 1001 SPATIAL LAYOUT, "C” BUILDING BLOCKS.”
  • the operator is addition of 200 ⁇ L of THF to all the spatial addresses in the row or cycle.
  • the seventh operator allows the reaction plates to stand at 25 decrees centigrade for 16 hrs. enabling evaporation of THF and completion of the synthesis of the molecular constructs.
  • reaction plates each address
  • 325 ⁇ L of DMSO place in the same microtiter plates
  • perator 10 This affords 29.4 mM solutions of the molecular constructs in DMSO ready for further spacial distribution.

Abstract

This invention is directed to an m x n array of different chemical compounds wherein each of said compounds has at least one structural diversity element selected from a group of amines and ketones and wherein the scaffold structure is selected from a group consisting of aminimide, imidazolone, sulfonylaminimide and phosphonylaminimide.

Description

A METHOD OF GENERATING A PLURALITY OF CHEMICAL COMPOUNDS IN A SPATIALLY ARRANGED ARRAY
Background of the Invention
The discovery of new molecules has traditionally focused in two broad areas, biologically active molecules, which are used as drugs for the treatment of life-threatening diseases, and new materials, which are used in commercial, especially high technological applications. In both areas, the strategy used to discover new molecules has involved two basic
operations: (i) a more or less random choice of a molecular candidate, prepared either via chemical synthesis or isolated from natural sources, and (ii) the testing of the molecular candidate for the property or properties of interest. This discovery cycle is repeated indefinitely until a molecule possessing the desirable properties is located. In the majority of cases, the molecular types chosen for testing have belonged to rather narrowly defined chemical classes. For example, the discovery of new peptide hormones has involved work with peptides; the discovery of new therapeutic steroids has involved work with the steroid nucleus; the discovery of new surfaces to be used in the construction of computer chips or sensors has involved work with inorganic materials, etc. (for example, see R. Hirschmann, Angetv.
Chem., Int. Ed. in Engl. 1991, 30, 1278-1301). As a result, the discovery of new functional molecules, being, ad hoc in nature and relying predominantly on serendipity, has been an extremely time-consuming, laborious, unpredictable, and costly enterprise.
A brief account of the strategies and tactics used in the discovery of new molecules is described below. The emphasis is on biologically interesting molecules. However, as discussed below, there are technical problems encountered in the discovery of molecules and in the development of fabricated materials which can serve as new materials for high technological applications.
Modern theories of biological activity state that biological activities, and therefore physiological states, are the result of molecular recognition events. For example, nucleotides can form complementary base pairs so that
complementary single-stranded molecules hybridize resulting in double- or triple-helical structures that appear to be involved in regulation of gene expression. In another example, a biologically active molecule, referred to as a ligand, binds with another molecule, usually a macromolecule referred to as ligand-acceptor (e.g. a receptor or an
enzyme), and this binding elicits a chain of molecular events which ultimately gives rise to a physiological state, e.g. normal cell growth and differentiation, abnormal cell growth leading to carcinogenesis, blood-pressure regulation, nerve-impulse-generation and -propagation, etc. The binding between ligand and ligand-acceptor is geometrically
characteristic and extraordinarily specific, involving appropriate three-dimensional structural arrangements and chemical interactions. Design and Synthesis of Mimetics of Biological Ligands
A currently favored strategy for development of agents which can be used to treat diseases involves the discovery of forms of ligands of biological receptors, enzymes, or related macromolecules, which mimic such ligands and either boost (i.e., agonize) or suppress (i.e., antagonize) the activity of the ligand. The discovery of such desirable ligand forms has traditionally been carried out either by random screening of molecules (produced through chemical synthesis or isolated from natural source's, for example, see K. Nakanishi, Acta Pharm. Nord., 1992, 4, 319-328.), or by using a so-called "rational" approach involving identification of a lead-structure, usually the structure of the native ligand, and optimization of its properties through numerous cycles of structural redesign and biological testing (for example see Testa, B. & Kier, L. B. Med. Res. Rev. 1991, 11, 35-48 and Rotstein, S. H. & Murcko, M. A. J. Med. Chem. 1993, 36, 1700-1710.). Since most useful drugs have been discovered not through the "rational" approach but through the screening of randomly chosen compounds, a hybrid approach to drug
discovery has recently emerged which is based on the use of combinatorial chemistry to construct huge libraries of randomly-built chemical structures which are screened for specific biological activities. (Brenner, S. & Lerner, R. A. Proc. Natl. Acad. Sci. USA 1992, 89, 5381)
Most lead-structures which have been used in "rational" drug design are native polypeptide ligands of receptors or enzymes. The majority of polypeptide ligands, especially the small ones, are relatively unstable in physiological fluids, due to the tendency of the peptide bond to undergo facile hydrolysis in acidic media or in the presence of peptidases. Thus, such ligands are decisively inferior in a
pharmacokinetic sense to nonpeptidic compounds, and are not favored as drugs. An additional limitation of small peptides as drugs is their low affinity for ligand acceptors. This phenomenon is in sharp contrast to the affinity demonstrated by large, folded polypeptides, e.g., proteins, for specific acceptors, e.g., receptors or enzymes, which can be in the subnanomolar range. For peptides to become effective drugs, they must be transformed into nonpeptidic organic structures, i.e., peptide mimetics, which bind tightly, preferably in the nanomolar range, and can withstand the chemical and
biochemical rigors of coexistence with biological fluids.
Despite numerous incremental advances in the art of peptidomimetic design, no general solution to the problem of converting a polypeptide-ligand structure to a peptidomimetic has been defined. At present, "rational" peptidomimetic design is done on an ad hoc basis. Using numerous redesign-synthesis-screening cycles, peptidic ligands belonging to a certain biochemical class have been converted by groups of organic chests and pharmacologists to specific
peptidomimetics; however, in the majority of cases the results in one biochemical area e.g., peptidase inhibitor design using the enzyme substrate as a lead, cannot be transferred for use in another area, e.g., tyrosine-kinase inhibitor design using the kinase substrate as a lead.
In many cases, the peptidomimetics that result from a peptide structural lead using the "rational" approach
comprise unnatural amino acids. Many of these mimetics exhibit several of the troublesome features of native
peptides (which also comprise alpha-amino acids) and are, thus, not favored for use as drugs. Recently, fundamental research on the use of nonpeptide scaffolds, such as
steroidal or sugar structures, to anchor specific receptor-binding groups in fixed geometric relationships have been described (see for example Hirschmann, R. et al. J. Am. Chem. Soc. 1992, 114, 9699-9701; Hirschmann, R. et al., J. Am.
Chem. Soc, 1992, 114, 9217-9218); however, the success of this approach remains to be seen.
In an attempt to accelerate the identification of lead- structures, and also the identification of useful drug candidates through screening of randomly chosen compounds, researchers have developed automated methods for the
generation of large combinatorial libraries of peptides and certain types of peptide mimetics, called "peptoids", which are screened for a desirable biological activity (see Gordon, E. M. et al. J. Med. Chem. 1994, 37, 1385-1401). For
example, the method of H. M. Geysen, (Bioorg. Med. Chem.
Letters, 1993, 3, 397-404; Proc. Natl. Acad. Sci. USA 1984, 81, 3998) employs a modification of Merrifield peptide synthesis, wherein the C-terminal amino acid residues of the peptides to be synthesized are linked to solid-support particles shaped as polyethylene pins; these pins are treated individually or collectively in sequence to introduce
additional amino-acid residues forming the desired peptides. The peptides are then screened for activity without removing them from the pins. Houghton, (Proc. Natl. Acad. Sci. USA 1985, 82, 5131; Eichler, J. & Houghton, R. A. Biochemistry, 1993, 32, 11035-11041, and U.S. Patent NO. 4,631,211)
utilizes individual polyethylene bags ( tea bags") containing C-terminal amino acids bound to a solid support. These are mixed and coupled with the requisite amino acids using solid phase synthesis techniques. The peptides produced are then recovered and tested individually. S. P. A. Fodor et al., (Science 1991, 251, 767) described light-directed, spatially addressable parallel-peptide synthesis on a silicon wafer to generate large arrays of addressable peptides that can be directly tested for binding to biological targets. These workers have also developed recombinant DNA/genetic
engineering methods for expressing huge peptide libraries on the surface of phages (Cwirla et al. Proc. Natl. Acad. Sci. USA 1990, 87, 6378; Barbas, et al. Proc. Natl. Acad. Sci. USA 1991, 881, 7978-7982).
In another combinatorial approach, V. D. Huebner and D.V. Santi (U.S. Patent No. 5,182,366) utilized
functionalized polystyrene beads divided into portions each of which was acylated with a desired amino acid; the bead portions were mixed together, then divided into portions each of which was re-subjected to acylation with a second
desirable amino acid producing dipeptides, using the
techniques of solid phase peptide synthesis. By using this synthetic scheme, exponentially increasing numbers of
peptides were produced in uniform amounts which were then separately screened for a biological activity of interest.
Zuckermann and coworkers (For examples, see Zuckermann, et al. J. Med. Chem. 1994, 37, 2678-2685 & Zuckermann, et al. Int. J. Peptide Protein Res. 1992, 91, 1) also have developed similar methods for the synthesis of peptide libraries and applied these methods to the automation of a modular
synthetic chemistry for the production of libraries of N-alkyl glycine peptide derivatives, called "peptoids", which are screened for activity against a variety of biochemical targets. (See also, Symon et al., Proc. Natl. Acad. Sci. USA, 1992, 89, 9367). Encoded combinatorial chemical
syntheses have been described recently (Brenner, S. & Lerner, R. A. Proc. Natl. Acad. Sci. USA 1992, 89, 5381; Barbas, C. F. et al. Proc. Natl. Acad. Sci. USA 1992, 89, 4,57-4461; see also Borchardt, A. & Still, W. C. J. Am. Chem. Soc. 1994, 226", 373-374; Kerr, J. et al. J. Am. Chem. Soc. 1993, 225, 2529-2531).
M. J. Kurth and his group (Chen, C. et al. J. Am. Chem. Soc. 1994, 116, 2661-2662.) have applied organic synthetic strategies to develop non-peptide libraries synthesized using multi-step processes on a polymer support. Although the method demonstrates the utility of standard organic synthesis in the application and development of chemical libraries, the synthetic conditions are limited by compatibility with the solid support.
The development of substrates or supports to be used in separations has involved either the
polymerization/crosslinking of monomeric molecules under various conditions to produce fabricated materials such as beads, gels, or films, or the chemical modification of various commercially available fabricated materials e.g., sulfonation of polystyrene beads, to produce the desired new materials. In the majority of cases, prior art support materials have been developed to perform specific separations or types of separations and are thus of limited utility.
Many of these materials are incompatible with biological macromolecules, e.g., reverse-phase silica frequently used to perform high pressure liquid chromatography can denature hydrophobic proteins and other polypeptides. Furthermore, many supports are used under conditions which are not
compatible with sensitive biomolecules, such as proteins, enzymes, glycoproteins, etc., which are readily denaturable and sensitive to extreme pH's. An additional difficulty with separations carried out using these supports is that the separation results are often support-batch dependent, i.e. they are irreproducible.
Recently a variety of coatings and composite-forming materials have been used to modify commercially available fabricated materials into articles with improved properties; however the success of this approach remains to be seen.
If a chromatographic support is equipped with molecules which bind specifically with a component of a complex
mixture, that component will be separated from the mixture and may be released subsequently by changing the experimental conditions (e.g., buffers, stringency, etc.) This type of separation is appropriately called "affinity chromatography" and remains an extremely effective and widely used separation technique (see Perry, E. S. in Techniques of Chemistry, Vol. 12 (J. Wiley) & May, S. W. in Separations and Purification 1978, 3rd ed.). It is certainly much more selective than traditional chromatographic techniques, e.g chromatography on silica, alumina, silica or alumina coated with long-chain hydrocarbons, polysaccharide and other types of beads or gels which in order to attain their maximum separating efficiency need to be used under conditions that are damaging to
biomolecules, e.g., conditions involving high pressure, use of organic solvents and other denaturing agents, etc. (for example see Stewart, D. J., et al. J. Biotechnology 1989, 22, 253-266; Brown, E., et al. Int. Symp. Affinity.
Chromatography & Molecular Interactions 1979, 86, 37-50).
The development of more powerful separation technologies depends significantly on breakthroughs in the field of materials science, specifically in the design and constructon of materials that have the power to recognize specific molecular shapes under experimental conditions resembling those found in physiological media, i.e. , these experimental conditions must involve an aqueous medium whose temperature and pH are close to the physiological levels and which contains none of the agents known to damage or denature biomolecules. The construction of these "intelligent" materials frequently involves the introduction of small molecules capable of specifically recognizing others into existing materials, e.g. surfaces, films, gels, beads, etc., by a wide variety of chemical modifications; alternatively molecules capable of recognition are converted to monomers and used to create the "intelligent" materials through polymerization reactions.
Advances in the ability to synthesize large numbers of peptides have made it possible to create a vast array of combinations of microenvironments within which different proteins may interact in equally. Kauvar (U.S. Patent
5,340,474) has developed a chromatographic method to obtain ligands which have the required affinity specific for a selected member of an array of analytes by providing maximal diversity in the choice of these ligands. A key to this technology is the use of a flow-through 96-well plate
compatible for assaying large numbers of parallel samples. Their short peptide-based ligands as paratope analogs (or "paralogs") contain an N-terminal amino acid spacer used for coupling to the sorbent. The C-terminal is capped with an amide group. Diversity is then created with the use of hydrophobic amino acids, enantiomeric amino acids, positively charged, negatively charged, and neutral (hydrophilic) residues, as well as intra-chain cyclization via the
formation of disulfide bonds between cysteine residues.
Protein is then loaded onto each column in the sorbent plate, and the proteins that are bound to the chromatographic sorbents are eluted, then collected into a second pretreated microplate (Benedek, K. et al. J. Chromatography 1992, 627, 51-61). Sets of paralogs are constructed by systematically varying five independent parameters drawn from protein structure literature: 1. a hydrophobic index; 2. an
isoelectric point derived from overall charge by averaging the pKa values of the ionizable side chains in solution at pH 7; 3. a hydrophobic moment; 4. an analogous lateral dipole moment; 5. a corrugation factor, defined as the measure of the scattering in the distribution of bulky side chains along the helical backbone (see Villar, H. O. & Kauvar, L. M. FEBS Letters 1994, 349, 125-130) and to defined reproducible patterns of cross-reaction which represent distinctive spectra of the primary antigen and its analogs using an immunoassay of molecular analogs against panels of antibodies (Cheung, P. Y. K., et al. Analytica Chimica Acta 1993, 283, 181-192)
Definitions
This invention discloses a system for the design, synthesis and use of logically arranged collections of synthetic product molecules called "molecular constructs" from structural elements in such a manner that the collection of molecular constructs possesses a constant structural element and a variable structural element. The definitions are shown below.
A "construct" is a molecule which is a member of a collection of molecules containing a common constant
structural element and a common variable structural element.
An "array" is a logical positional ordering of molecular constructs in Cartesian coordinates.
A "bond" or "chemical bond" is used to describe a group of electrons that is shared between two atoms. This term also denotes an ionic, covalent or other attractive force between two atoms.
A "building block" is any molecule useful in the
assembly of a molecular construct.
The terms "fragment" or "structural diversity element" refer to the common variable structural element of a
molecular construct.
The "molecular core" is the common constant structural element of a molecular construct.
A "spatial address" is a position in the array defined by unique Cartesian coordinates.
A "sub-array" is a set of spatial addresses within a given array containing those molecular constructs having a common molecular core and differ from each other by 0 (zero) or 1 (one) change in a fragment.
A "relative address" refers to a location within the array or sub array comparable to any selected address, and differing by 0 (zero) or only 1 (one) change in the common variable structural element.
An "operator" is a simultaneous and/or concurrent change in the condition of at least two spatial addresses in
individual cells residing in an array or a sub-array that results in a structural change in at least one molecular construct in the array. In particular, an operator in terms of this invention can be the reaction of at least one site on the molecular core capable of becoming or providing
attachment for a structural diversity element, to add or change a structural motif thereon. Other operators which can be performed according to the patent include but are not limited to: addition of reagents or solvents; quality control protocols such as gas chromatography, high performance liquid chromatography, mass spectrometry, infrared spectroscopy, ultraviolet spectroscopy, nuclear magnetic resonance
spectroscopy, fluorescence spectroscopy, melting point, mass balance, combustion analysis and thin layer chromatography; biological and enzymological assays such as ELISA,
spectroscopic inhibition assays, disc assays and binding affinity assays; mechanical motions or manipulations; passage of time which includes resting & evaporation; heating and cooling; iteration of previous steps in a synthesis;
dilution and dispensation of products in a form suitable for the design purpose.
SUMMARY OF THE INVENTION
This invention is directed to an m × n array of
different chemical compounds wherein each of said compounds has at least one structural diversity elements chosen from the group consisting of:
Figure imgf000013_0001
and wherein the scaffold structure is selected from the group consisting of:
Figure imgf000013_0002
This invention is still further directed to an m × n array of different chemical compounds wherein each of said compounds has at least one of the structural diversity elements defined herein and wherein the scaffold structure may be a chemical molecule having at least three carbon atoms and at least two sites on the molecule capable of undergoing a reaction to change the structure, usually by the addition of other- molecules to a site capable of reacting to form or attach a structural diversity element.
This invention is still yet further directed to an n × m array of chemical compounds called molecular constructs possessing a logical ordering of molecular constructs
comprising at least one k × l sub array within the array wherein each sub array is comprised of
a) at least k.l molecular constructs having a common molecular core and differing from the other k.l molecular constructs in the sub array by at least one change in the structural diversity
element attached to the molecular core; and b) each sub array within the array is related to all other sub arrays in that all corresponding molecular constructs within each sub array has at least one change in the structural diversity
elements.
Also, the array of chemical compounds above encompasses those circumstances wherein n, m, k and 1 are all integers greater than 1.
The above array of chemical compounds can also be directed to those circumstances wherein n > 5 and m > l, or n > 10 and m > 1, or even wherein n > 5 and m > 5. The specific integers used for m and n are not critical and any can be selected depending upon the desired form of the array.
The above defined array of chemical compounds is also directed to arrays wherein m multiplied by n is greater than 10, greater than 20, greater than 100, greater than 200, greater than 500, greater than 1000 or even greater than 5000. Again, the final number can be any multiple of the selected m and n values.
Still yet further the present invention is directed to an n × m array of chemical compounds called molecular
constructs possessing a logical ordering of molecular
constructs comprising at least one k × 1 sub array within the array the wherein each sub array is comprised of a) at least K.l molecular constructs having a common molecular core and differing from other k.l molecular constructs in the sub array by at least one change in the structural diversity element attached to the molecular core;
b) each sub array within the array is related to all other sub arrays in that all corresponding molecular constructs with each sub array has at least one change in the structural diversity elements; and
c) and wherein each molecular construct is equidistant from at least two of its neighboring molecular constructs.
A preferred array is that defined immediately above wherein when n and m are greater than 3 and the chemical compounds are surrounded on four sides by four equidistant neighboring other chemical compounds.
Also the present invention covers n × m arrays of chemical compounds called molecular constructs possessing a logical ordering of molecular constructs comprising at least one k × l sub array within the array wherein each sub array is comprised of
a) at least k.l molecular constructs having a common molecular core and differing from the other k.l molecular constructs in the sub array by at least one change in the structural diversity element attached to the molecular core; b) each sub array within the array is related to all other sub arrays in that all corresponding molecular constructs within each sub array has at least one change in the structural diversity elements; and
c) and wherein each molecular construct is separated from all other molecular constructs by a container material.
The contained materials for the above cited array may employ glass, polymers, silicon, or any other material known by those of ordinary skill in the art.
Further, the present invention is directed to an n × m × q array of chemical compounds called molecular constructs possessing a logical ordering of molecular constructs
comprising at least one k × l sub array within the array wherein each sub array is comprised of
a) at least k.l molecular constructs having a common molecular core and differing from the other k. l molecular constructs in the sub array by at least one change in the structural diversity element attached to the molecular core;
b) each sub array within the array is related to all other sub arrays in that all corresponding molecular constructs within each sub array has at least one change in the structural diversity elements; and
c) and wherein q is an integer > 1 and each array designated q1...qs where s is an integer > than 1, differs from the other q arrays by at least one function.
In addition, the present invention is directed to an n × m × q array wherein the function is the addition of an organic structure selected from the group consisting of an amine, an aldehyde, an alcohol, a ketone, a carboxylic acids, an ether and an epoxy, and wherein the function may or may not be an analytic technique.
The reactions which are the subject of this invention may be performed simultaneously by using a mechanical
apparatus such as multiple pipettes attached to an apparatus and other methods known to the skilled artisan. Brief Description of Drawings
Figure 1 is a graphical representation of an array vertex illustrating the relationship between the building blocks, their addresses and the various operators therefor; and
Figure 2 is a schematic diagram representing the
sequence of events for combining the building blocks to form the array.
Detailed Description of the Invention
This invention pertains to the logical layout,
construction and testing of arrays of chemical compound for one of a variety of applications, in which the desired properties of the compound can be measured and correlated to specific ordered changes in the fragments use to construct them. The array is ordered in such a fashion as to expedite assembly, to maximize the informational content derived from the testing and to facilitate the rapid extraction of that data from the testing process. This method has great utility in accelerating the development of compounds have the optimal properties for the desired application.
The arrays are constructed from logically ordered and arranged sub-arrays of compounds. Each sub-array consists of spatially addressable sets of structurally related individual chemical compounds, ranging in number from one to 1012 and possessing the following properties: (1) a. common structural scaffold element referred to as a "molecular core" and (2) a variable structural diversity element referred to as a fragment, in such a manner that the variation between any two compounds within a given sub-array consists only of either zero (0) or one (l) change in a fragment. These arrays may in turn be arranged in such a manner to form higher order arrays consisting of sets of arrays and tested to provide information regarding the optimum structural features available for the application.
The sub-arrays are arranged in such a manner that the direct comparisons of compounds automatically yields
information regarding the effect known fragments have on a desired application, as well as on the effect on changes in physical and reactive properties. As provided by simple set theory for any number of independently variable structural diversity elements n, there exists n logical higher order array arrangements, such that relational information on the effect of variation of each of the a structural diversity elements can be obtained in a similar manner by comparison of testing data from the relative addresses in appropriately arranged sub-arrays.
An application of this invention is the rapid
determination and optimization of desired biological or physical activity. An array is screened and the optimum candidate is chosen. This process can be continued in n dimensions to provide an absolute structure activity
relationship ("SAR") picture of the candidate and selection in speeded by the rapid modular synthesis of arrays for use in testing. Thus in one light the invention is the most powerful tool to date for the rapid synthesis, screening and testing of compounds for IND candidacy. This method is facilitated by virtue of selecting fragments based solely upon their ability to react and participate in the process of assembly.
These arrays may be assembled to form a "super array" for exhaustive testing. This approach provides a large scale view over different structures, functionalities and spatial arrangements for exploring biological activity.
The physical construction of the array also permits the logical and rapid analysis of synthetic results for the assurance of purity and quality. By testing a series of loci within any given sub-array, it becomes possible to determine the efficacy of construction of that core, and eliminate those fragments (i.e., process development within the
assembly) which do not provide satisfactory results. This system, therefore possesses the ability to learn the utility of given reagents from previous results, and either delete them from further use or alter general conditions for their efficient incorporation into the array. Thus, both positive and negative results are of value in the ultimate
construction of the array, and there is no ambiguity in regards to the inclusion or exclusion of fragments.
A further application of this invention is the
facilitation of the optimal analyte or epitope binding ligand for attachment to a chromatographic support for separation or purification applications. A further application of this invention pertains to the ability to construct materials in a modular fashion, so as to facilitate their selection for such properties as strength, stability, reactivity or any other desired physical property. Whereas many methods rely upon logical choice for fragment candidates in such efforts, this method provides for the construction and testing of all candidates, thereby eliminating any compromises which
traditional methods make based on the limits of time,
manpower, and cost. By the screening of all possible
synthetic variations the selection of the optimal candidate is a matter of data and not chemical intuition. The desired affinity can be rapidly optimized and directly correlated and attributed to the singular change made within a given sub-array. Therefore the selection of a ligand is no longer a random, intuitive process, but one of complete confidence providing exhaustive data (cf. Kauvar, L.M. U.S. Patent
5,340,474).
Furthermore the invention provides for the development of seamless technology between planning, logistical
development, execution of assembly in either an arrayed or subarrayed manner, quality analysis, packaging, distribution, testing, interpretation and iteration. The invention
provides for the integrated design and delivery of a unified chemical discovery system, which by application of logic and implementation of information management, has been heretofore unknown. The invention provides for the occupation of all possible spatial addresses and therefore allows for complete analysis of desired properties. This concept can be extended toward the design and manufacture of appropriate hardware and software to support the integrated aspect of this modular construction.
The logically arranged arrays of the present invention are fundamentally different from all known prior art.
Testing of these arrays automatically results in the
generation of complete relational structural information such that a positive result provides: (1) information on a
compound within any given spatial address; (2) simultaneous juxtaposition of this information upon a set of
systematically structural congeners; (3) the ability to extract relational structural information from negative results in the presence of positive results.
All known prior art is universally directed toward the maximization of structural diversity. By definition this has excluded the acquisition of maximal data. In these cases, the relationship between individual structural variations and any resulting changes in a measurable property of the
compounds can not be directly obtained from the testing results. The process of obtaining a compound having a desired physical property using methods of the prior art, while guided by intuition, is a random statistical process at best. Thus a positive result is not designed to give any additional information about the relationship between a specific structural modification and the corresponding change in the desired property, and a negative result can not provide any information at all. Methods in the prior art universally require extensive further experimentation to elucidate any relational information in a process which is costly, time consuming and one in which success is difficult to predict.
These arrays may be constructed from a wide variety of molecular cores, several examples of whi :h are shown below. The criteria for core candidates are that the scaffold a) present attachment points for at least two structural diversity elements; b) is able to present these structural diversity elements in controlled, varying spatial
arrangements; c) can be constructed in a rapid concerted fashion.
In general the molecular cores are linear, branched or cyclic organic compounds. In particular, the molecular cores comprise a chemical molecule having at least three carbon atoms and at least two sites on the molecule capable of undergoing a reaction to change the structure, usually by the addition of other molecules to a site capable of reacting to form or attach a structural diversity element.
One example of a molecular core is an aminimide
molecule. This is a technology which has been previously described.
Figure imgf000021_0001
These compounds may be synthesized in a number of ways, from the reaction of an epoxide, an ester, and a hydrazine, as well as alkylation of a hydrazide, as shown below.
Figure imgf000021_0002
An example of a scaffold capable of forming a molecular core of an oxazolone molecule. Methylidene amides are formed from the sequential reaction of aldehydes, then amines with oxazolones. These compounds and their congeners may be in turn transformed into imidazolones:
Figure imgf000022_0001
These compounds and their methods of manufacture are
described in PCT Publications WO94/00509 and WO94/01102.
Sulfonylaminimides and phosphonylaminimides are still further examples of molecular cores which can be constructed in an analogous manner as their carbon-based counterparts, with the exception of sulfonate esters not participating in the reaction of an epoxide and hydrazine in the desired manner.
Figure imgf000022_0002
While the aminimide, oxazolone, sulphonylaminimide, and phosphonylaminimide are several examples of the concept of a molecular core, other molecular cores are possible according to the teachings of this invention. Further examples of possible molecular cores include, but are not limited to:
alkaloids, quinolines, isoquinolines, benzimidazoles,
benzothiazoles, purines, pyrimidines, thiazolidines,
imidazopyrazinones, oxazolopyridines, pyrroles, pyrrolidines, imidazolidones, quinolones, amino acids, macrolides, penems, saccharides, xanthins, benzothiadiazine, anthracyclines, dibenzocycloheptadienes, inositols, porphyrins, corrins, and carboskeletons presenting geometric solids (e.g.,
dodecahedrane).
Diels-Alder reactions, Darzens glycidic ester
condensations, Simmons-Smith cyclopropanations, rhodium catalyzed carbene additions, Ugi and Passerini reactions may all be done in such a manner, as to construct these arrays as described above. The application of this technology is facile and the format in which it is constructed is amenable to most organic transformations and reaction sequences.
The structural diversity elements may be the same or different, may be of a variety of structures and may differ markedly in their physical or functional properties, or may be the same; they may also be chiral or symmetric or from a compound which is chiral or symmetric. The structural diversity elements are preferably selected from:
1) amino acid derivatives of the form (AA)n, which would include, for example, natural and synthetic amino acid residues (n = 1) including all of the naturally occurring alpha amino acids, especially alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine,
phenylalanine, proline, serine, threonine, tryptophan, tyrosine; the naturally occurring disubstituted amino acids, such as amino isobutyric acid, and isovaline, etc.; a variety of synthetic amino acid residues, including alpha- disubstituted variants, species with olefinic substitution at the alpha position, species having derivatives, variants or mimetics of the naturally occurring side chains; N-substituted glycine residues; natural and synthetic species known to functionally mimic amino acid residues, such as statine, bestatin, etc. Peptides (n = 2 - 30) constructed from the amino acids listed above, such as angiotensinogen and its family of physiologically important angiotensin hydrolysis products, as well as derivatives, variants and mimetics made from various combinations and permutations of all the natural and synthetic residues listed above.
Polypeptides (n = 31 - 70), such as big endothelin,
pancreastatin, human growth hormone releasing factor and human pancreatic polypeptide. Proteins (n > 70) including structural proteins such as collagen, functional proteins such as hemoglobin, regulatory proteins such as the dopamine and thrombin receptors.
2) a nucleotide derivative of the form (NUCL)n, which includes natural and synthetic nucleotides (n = 1), such as adenosine, thymine, guanidine, uridine, cytosine, derivatives of these and a variety of variants and mimetics of the purine ring, the sugar ring, the phosphate linkage and combinations of some or all of these. Nucleotide probes (n = 2 - 25) and oligonucleotides (n > 25) including all of the various possible; homo and hetero-synthetic combinations and
permutations of the naturally occurring nucleotides;
derivatives and variants containing synthetic purine or pyrimidine species, or mimics of these; various sugar ring mimetics; and a wide variety of alternate backbone analogs, including but not limited to phosphodiester,
phosphorothionate, phosphorodithionate, phosphoramidate, alkyl phosphotriester, sulfamate, 3,-thioformacetal,
methylene(methylimino), 3-N-carbamate, morpholino carbamate and peptide nucleic acid analogs.
3) a carbohydrate derivative of the form (CH)n, which would include natural physiologically active carbohydrates; related compounds, such as glucose, galactose, sialic acids, iS-D-glucosylamine and nojorimycin, which are both inhibitors of glucosidase; pseudo sugars, such as 5a-carba-2-D- galactopyranose, which is known to inhibit the growth of Klebsiella pneumonia (n = 1); synthetic carbohydrate residues and derivatives of these (n = 1) and all of the complex oligomeric permutations of these as found in nature,
including high mannose oligosaccharides, the known antibiotic streptomycin (n > 1).
4) a naturally occurring or synthetic organic structural motif. The term "motif" is defined as an organic molecule having or containing a specific structure that has biological activity, such as a molecule having a
complementary structure to an enzyme active site, for
example. This term includes any of the well known basic structures of pharmaceutical compounds including
pharmacophores, or metabolites thereof. These basic
structures include beta-lactams, such as penicillin, known to inhibit bacterial cell wall biosynthesis; dibenzazepines, known to bind to CNS receptors and used as antidepressants; polyketide macrolides, known to bind to bacterial ribosymes, etc. These structural motifs are generally known to have specific desirable binding properties to ligand acceptors.
5) a reporter element, such as a natural or synthetic dye or a residue capable of photographic amplification which possesses reactive groups that may be synthetically
incorporated into the sulfaminimide structure or reaction scheme, and may be attached through the groups without adversely interfering or affecting with the reporting
functionality of the group. Preferred reactive groups are amino, thio, hydroxy, carboxylic acid, carboxylic acid ester, particularly methyl ester, acid chloride, isocyanate alkyl halides, aryl halides and oxirane groups.
6) an organic moiety containing a polymerizable group such as a double bond, or other functionalities capable of undergoing condensation polymerization or copolymerization. Suitable groups include vinyl groups, oxirane groups,
carboxylic acids, acid chlorides, esters, amides, azlactones, lactones and lactams. Other organic moiety such as those defined for R and R' may also be used.
7) a macromolecular component, such as a macromolecular surface or structures which may be attached to the
sulfaminimide modules via the various reactive groups
outlined above, in a manner where the binding of the attached species to a ligand-receptor molecule is not adversely affected and the interactive activity of the attached
functionality is determined or limited by the macromolecule. Examples of macromolecular components include porous and non-porous inorganic components, such as, for example, silica, alumina, zirconia, titania and the like, as commonly used for various applications, such as normal and reverse phase chromatographic separations, water purification, pigments for paints, etc.; porous and non-porous organic macromolecular components, including synthetic components such as
styrenedivinyl benzene beads, various methacrylate beads, PVA beads, and the like, commonly used for protein purification, water softening; and a variety of other applications, natural components such as native and functionalized celluloses, such as, for example, agarose and chitin, sheet and hollow fiber membranes made from nylon, polyether sulfone or any of the materials mentioned above. The molecular weight of these macromolecules may range from about 1000 Daltons to as high as possible. They may take the form of nano-particles (dp = 1000 - 5000 Angstroms), latex particles (dp = 1000 - 5000 Angstroms), porous or non-porous beads (dp = 0.5 - 1000 microns), membranes, gels, macroscopic surfaces or
functionalized or coated versions or composites.
Structural diversity elements may also be a chemical bond to a suitable organic moiety, a hydrogen atom, an organic moiety which contains a suitable electrophilic group, such as an aldehyde, ester, alkyl halide, ketone, nitrile, epoxide or the like; a suitable nucleophilic group, such as a hydroxyl, amino, carboxylate, amide, carbanion, urea or the like; or one of the other structural diversity elements defined below. In addition, structural diversity elements may join to form a ring, bi-cyclic or tri-cyclic ring system; or structure which connects to the ends of the repeating unit of the compound defined by the preceding formula; or may be separately connected to other moieties.
Structural diversity elements on a scaffold may be the same or different and each may be one or more atoms of carbon, nitrogen, sulfur, oxygen, any other inorganic
elements or combinations thereof. The structural diversity elements may be cyano, nitro, halogen, oxygen, hydroxy, alkoxy, thio, straight or branched chain alkyl, carbocyclic aryl and substituted or heterocyclic derivatives thereof.
Structural diversity elements may be different in adjacent molecular cores and have a selected stereochemical
arrangement about the carbon atom to which they are attached.
As used herein, the phrase linear chain or branched chained alkyl groups means any substituted or unsubstituted acyclic carbon-containing compounds, including alkanes, alkenes and alkynes. Alkyl groups having up to 30 carbon atoms are preferred. Examples of alkyl groups include lower alkyl, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl; upper alkyl, for example, octyl, nonyl, decyl, and the like; lower alkylene, for example, ethylene, propylene, propyldiene, butylene,
butyldiene; upper alkenyl such as 1-decene, 1-nonene, 2,6-dimethyl-5-octenyl, 6-ethyl-5-octenyl or beptenyl, and the like; alkynyl such as 1-ethynyl, 2-butynyl, 1-pentynyl and the like. The ordinary skilled artisan is familiar with numerous linear and branched alkyl groups, which are within the scope of the present invention.
In addition, such alkyl group may also contain various substituents in which one or more hydrogen atoms has been replaced by a functional group. Functional groups include but are not limited to hydroxyl, amino, carboxyl, amide, ester, ether, and halogen (fluorine, chlorine, bromine and iodine), to mention but a few. Specific substituted alkyl groups can be, for example, alkoxy such as methoxy, ethoxy, butoxy, pentoxy and the like, polyhydroxy such as 1,2-dihydroxypropyl, 1,4-dihydroxy-1-butyl, and the like;
methylamino, ethylamino, dimethylamino, diethylamino,
triethylamino, cyclopentylamino, benzylamino, dibenzylamino, and the like; propionic, butanoic or pentanoic acid groups, and the like; formamido, acetamido, butanamido, and the like, methoxycarbonyl, ethoxycarbonyl or the like, chloroformyl, bromoformyl, 1, 1-chloroethyl, bromoethyl, and the like, or dimethyl or diethyl ether groups or the like.
As used herein, substituted and unsubstituted carbocyclic groups of up to about 20 carbon atoms means cyclic carbon-containing compounds, including but not limited to cyclopentyl, cyclohexyl, cycloheptyl, adamantyl, and the like. Such cyclic groups may also contain various
substituents in which one or more hydrogen atoms has been replaced by a functional group. Such functional groups include those described above, and lower alkyl groups as described above. The cyclic groups of the invention may further comprise a heteroatom. For example, in a specific embodiment, structural diversity element A is cyclohexanol.
As used herein, substituted and unsubstituted aryl groups means a hydrocarbon ring bearing a system of
conjugated double bonds, usually comprising (4p - 2) pi bond electrons, where p is an integer equal to or greater than 1. Examples of aryl groups include, but are not limited to, phenyl, naphthyl, anisyl, toluyl, xylenyl and the like.
According to the present invention, aryl also includes aryloxy, aralkyl, aralkyloxy and heteroaryl groups, e.g., pyrimidine, morpholine, piperazine, piperidine, benzoic acid, toluene or thiophene and the like. These aryl groups may also be substituted with any number of a variety of
functional groups. In addition to the functional groups described above in connection with substituted alkyl groups and carbocyclic groups, functional groups on the aryl groups can be nitro groups.
As mentioned above, structural diversity elements can also represent any combination of alkyl, carbocyclic or aryl groups; for example, 1-cyclohexylpropyl,
benzylcyclohexylmethyl, 2-cyclohexyl-propyl,
2,2-methylcyclohexylpropyl, 2,2methylphenylpropyl,
2,2-methylphenylbutyl, and the like.
The structural diversity element may also be a
connecting group that includes a terminal carbon atom for attachment to the quaternary nitrogen and may be different in v djacent n units.
In one embodiment of the invention, at least one of the structural diversity elements represents an organic or inorganic macromolecular surface. Examples of preferred macromolecular surfaces include ceramics such as silica and alumina, porous and non-porous beads, polymers such as a latex in the form of beads, membranes, gels, macroscopic surfaces or coated versions or composites or hybrids thereof.
All publications, patents, and patent applications are herein specifically incorporated by reference to their relevant portions (cf. The Merck Index, 11th Ed., Budavari, S. Ed., Merck & Co., Rahway, NJ, 1989; Physicians Desk
Reference, 44th Ed., Barnhart, E. D. Publ., Medical Economics Company Inc., Oradell, NJ, 1990.
The following experimentals are meant to exemplify but one embodiment of the present invention and are not intended to limit the invention thereto.
Examples
A 10,240-component array is synthesized according to the teaching of the invention, from eight oxazolones (Building Block A), 32 aldehydes (Building Block B), and 40 amines (Building Block C).
AN 1001 Protocol: Tetrahydrofuran (THF) solutions of the building blocks are prepared according to the protocols generated on the spread sheets entitled "AN 1001 SOLUTION PROTOCOLS. CALCULATIONS, AND BUILDING BLOCK SELECTION". The Building Block solutions are 250 mM in "A", 250 mM in "B", and 500 mM in "C". Sufficient volumes of each solution are prepared to allow for the production of one row of reaction plates (Px, where x= 1-128 for AN 1001). A reaction plate contains 80 spatial addresses each (8 X 10) and a row
contains 16 reaction plates. The entire array consists of 8 rows of these reaction plates which are recycled 16 at a time to complete production of the array. The initial cycle's first operator is spatial delivery of 200 μl (1 eq., 50 μmoles) of the "A" building block solution according to the spread sheet entitled "AN 1001 SPATIAL LAYOUT, "A" BUILDING
BLOCKS" starting at P1 and ending at P16. The second
operator is spatial delivery of 200 μl (1 eq., 50 μmoles) of the "B" Building Blocks to the same reaction plates according to the spread sheet entitled "AN 1001 SPATIAL LAYOUT, "B" BUILDING BLOCKS." The third operator is addition to the same reaction plates of 50 μL of a I M (1 eq., 50 μmoles) solution of triethylamine in THF to all the spatial addresses that "A" and "B" building Blocks were added. The forth operator is placement of the reaction blocks on an agitator at 60 degrees centigrade for 1.5 hrs. The fifth operator is spatial addition of 100 μl (1 eq., 50 μmoles) of the "C" building, block solutions according to the spread sheet entitled "AN 1001 SPATIAL LAYOUT, "C" BUILDING BLOCKS." The sixth
operator is addition of 200 μL of THF to all the spatial addresses in the row or cycle. The seventh operator allows the reaction plates to stand at 25 decrees centigrade for 16 hrs. enabling evaporation of THF and completion of the synthesis of the molecular constructs. The following
operators are then applied to distribute and reformat the molecular constructs for delivery and quality control. Heat the reaction plates to 60 degrees centigrade for 10 minutes and add 400 μl of dimethylsuIfoxide (DMSO) to dissolve the molecular constructs (operator 8). Remove the solution from the reaction plates and place in a plastic microtiter plates in a special manner (operator 9). Specially wash the
reaction plates (each address) with 4 times 325 μL of DMSO and place in the same microtiter plates (operator 10). This affords 29.4 mM solutions of the molecular constructs in DMSO ready for further spacial distribution. Remove a 10 μL aliquot following a unique address pattern layout from each microtiter plate for quality control (operator 11).
Specially reformat these aliquots, dilute with 300 μL of acetonitrile and subject these samples to analysis by High Performance Liquid Chromatography and Mass Spectrometry for quality control of the molecular constructs in the each microtiter plate (operator 12). The above cycles and
operators are repeated 7 more times to finish production and quality controlled validation of the array, AN 1001.
Figure imgf000031_0001
Figure imgf000032_0001
Figure imgf000033_0001
Figure imgf000034_0001
Figure imgf000035_0001
Figure imgf000036_0001
Figure imgf000037_0001
Figure imgf000038_0001
Figure imgf000039_0001
Figure imgf000040_0001
Figure imgf000041_0001
Figure imgf000043_0001
Figure imgf000044_0001
Figure imgf000045_0001
Figure imgf000046_0001
Figure imgf000047_0001
Figure imgf000048_0001
Figure imgf000049_0001
Figure imgf000050_0001
Figure imgf000051_0001
Figure imgf000052_0001
Figure imgf000053_0001
Figure imgf000054_0001
Figure imgf000055_0001
Figure imgf000056_0001
Figure imgf000057_0001
Figure imgf000058_0001
Figure imgf000059_0001
Figure imgf000060_0001
Figure imgf000061_0001
Figure imgf000062_0001
Figure imgf000063_0001
Figure imgf000064_0001
Figure imgf000065_0001
Figure imgf000066_0001
Figure imgf000067_0001
Figure imgf000068_0001
Figure imgf000069_0001
Figure imgf000070_0001
Figure imgf000071_0001
Figure imgf000072_0001
Figure imgf000073_0001
Figure imgf000074_0001
Figure imgf000075_0001
Figure imgf000076_0001
Figure imgf000077_0001
Figure imgf000078_0001
Figure imgf000079_0001
Figure imgf000080_0001
Figure imgf000081_0001
Figure imgf000082_0001
Figure imgf000083_0001
Figure imgf000084_0001
Figure imgf000085_0001
Figure imgf000086_0001
Figure imgf000087_0001
Figure imgf000088_0001
Figure imgf000089_0001
Figure imgf000090_0001
Figure imgf000091_0001
Figure imgf000092_0001
Figure imgf000093_0001
Figure imgf000094_0001
Figure imgf000095_0001
Figure imgf000096_0001
Figure imgf000097_0001
Figure imgf000098_0001
Figure imgf000099_0001
Figure imgf000100_0001
Figure imgf000101_0001
Figure imgf000102_0001
Figure imgf000103_0001
Figure imgf000104_0001
Figure imgf000105_0001
Figure imgf000106_0001
Figure imgf000107_0001
Figure imgf000108_0001

Claims

The Claims What is claimed is:
1. A method for constructing an array of synthetic molecular constructs, comprising the steps of:
a. forming a plurality of molecular constructs; b. laying out an array possessing a logical
ordering of sub-arrays of said molecular constructs;
c. providing each sub-array with molecular
constructs having a common molecular core and at least one structured diversity element which is different from the others; and
d. relating each sub-array within the array to all other sub arrays by said difference in said
structural diversity elements.
2. The method of Claim 1 where the molecular constructs are functionalized beads, plates, membranes, composites or combinations thereof.
3. A method of optimizing the ability of a first chemical compound to bind to a reaction site comprising the steps of:
a) ascertaining the three dimensional and
electrostatic configuration of the reaction site; b) selecting a scaffold backbone for attaching at least one structural diversity element that is complementary to the reaction site;
c) forming an n × mm array of different chemical compounds, wherein each chemical compound comprises said scaffold and at least one structural diversity element; and
d) simultaneously screening each of the compounds in the n × m array against the reaction site to determine the chemical compound having the most reactivity to the reaction site.
4. A method according to claim 3 which further - comprises (e) ascertaining which chemical compounds in the n × m array have any reactivity to the reaction site and assigning those compounds a location designated by (n,m).
5. A method according to claim 4 which further comprises (f) forming an o × p array comprising at least one of the compounds having reactivity to the reaction site and forming at least one homolog, isomer or analog of each of said at least one compound to form the o × p array.
6. A method according to claim 5 which further comprises (g) simultaneously screening each of the compounds in the o × p array to determine their reactivity to the reaction site.
7. A method according to claim 6 wherein steps (e) through (g) are repeated at least twice.
8. A method according to claim 1 which further comprises selecting the scaffold backbone to have the following structure:
Figure imgf000110_0001
9. A method according to claim 1 which further comprises selecting the scaffold backbone to have the following structure:
Figure imgf000110_0002
10. A method according to claim 1 which further comprises selecting the scaffold backbone to have the following structure:
Figure imgf000111_0001
11. A method according to claim 1 which further comprises selecting the scaffold backbone to have the following structure:
Figure imgf000111_0002
12. A method according to claim 1 which further comprises selecting the structural diversity elements is selected from the group consisting of but not limited to:
Figure imgf000112_0001
13. A method according to claim 3 wherein each compound having a binding ability is assigned a location in the array, which also provides structural and chemical data for that compound.
14. A method of ascertaining the spatial orientation of an n × m array of different chemical compounds comprising the steps of:
a) forming an n × m array of oriented wells;
b) adding reactive ingredients capable of forming chemical compounds into the wells;
c) determining the molecular weights of all ingredients added to each well and assigning each well a location (n,m);
d) allowing the reactive ingredients to combine to form a chemical compound in each well, and determining the molecular weight of the chemical compositions in any two wells;
e) matching the molecular weights of the chemical compounds in the any two wells with the molecular weights of the chemical ingredients added to each well (n,m) to determine the spatial orientation of the array.
15. A method according to claim 14 wherein the molecular weight is determined by mass spectroscopy.
16. A method of determining the structure of a chemical compound capable of binding to a reaction site comprising the steps of:
a) ascertaining the three dimensional structure and electrostatic configuration of the reaction site;
b) selecting a scaffold backbone for attaching structural diversity elements that is capable of being complementary to the reaction site; c) forming an n x m array of different chemical compounds, wherein each chemical compound comprises the scaffold backbone and at least one structural diversity element;
d) simultaneously screening each of the compounds in the n x m array against the reaction site to determine the chemical compound having the most reactivity to the molecular recognition site.
17. A method according to claim 16 wherein the scaffold has the structure:
Figure imgf000114_0001
18. A method according to claim 16 wherein the scaffold has the structure:
Figure imgf000114_0002
19. A method according to claim 16 wherein the scaffold has the structure:
Figure imgf000114_0003
20. A method according to claim 16 wherein the scaffold hps the structure:
Figure imgf000114_0004
21. A method according to claim 16 wherein at least one of the structural diversity elements is selected from the group consisting of but not limited to:
Figure imgf000115_0001
22. A method of determining the structure of at least a portion of a reaction site comprising the steps of a) selecting a scaffold backbone for attaching structural diversity elements;
b) forming an n × m array of different chemical compounds, wherein each chemical compound comprises the scaffold backbone and at least one structural diversity element;
c) simultaneously screening the n x m array against the reaction site to determine the chemical compound having the most reactivity to the reaction site;
d) determining the structure of the compound (n,m) in the array having the greatest reactivity; e) forming a second k × l array comprising the reactive compound having the greatest reactivity from the n × m array and its isomers, homologs and analogs;
f) simultaneously screening the k × l array of compounds against the reaction site to determine the chemical compound, having the greatest reactivity to the reaction site;
g) determining the structure and electrostatic configuration of the compound from the k × l array having the greatest reactivity;
f) forming at least one homolog, isomer or analog of each compound (n,m) having a reactivity to form the o × p array.
23. The rational development of a chemical
compound capable of reacting with a molecular recognition site comprising the steps of:
a) selecting a scaffold for attaching structural diversity elements;
b) simultaneously forming an n × m array of different chemical compounds, wherein each chemical compounds comprises a scaffold and at least one structural diversity element; and c) simultaneously screening the n × m array of compounds against a molecular recognition site to determine the chemical compound having the most reactivity to the molecular recognition site;
24. A method of forming an n × m array of chemical compounds comprising the steps of:
a) Forming an n × m array of the same molecular construct having a common molecular core and X, where X is greater than or equal to three, sites capable of undergoing chemical transformations;
b) simultaneously and/or concurrently performing an operation on each molecular construct in the n x m array to create a reaction on at least one site on each of the n × m molecules to form at least one different molecular construct;
c) performing either overlaid or orthogonal operations on the product of b. for sufficient cycles to produce an ordered, fully-addressable array of novel compounds.
25. A method of determining the structure of a chemical compound capable of binding to a reaction site comprising the steps of;
a) ascertaining the three dimensional structure and electrostatic configuration of the reaction site;
b) selecting a scaffold backbone for attaching structural diversity elements that is capable of being complementary to the reaction site; c) forming an n × m array of different chemical compounds, wherein each chemical compound comprises the scaffold backbone and at least one structural diversity element; and
d) simultaneously screening each of the compounds in the n × m array against the reaction site to determine the chemical compound having the most reactivity to the molecular recognition site.
26. A method according to claim 25 which further comprises the following steps:
e) simultaneously screening each of the compounds in the o × p array
f) determining the molecular weight of all ingredients added to each well and assigning each well a location (n,m);
g) allowing the reactive ingredients to combine to form a chemical compound in each well and determining the molecular weight of the chemical compositions in any two wells;
h) adding reactive ingredients capable of forming chemical compounds into the wells, is performed; and
i) simultaneously screening each of the compounds in the o × p array against a reactive site.
27. A method of determining the structure of at least a portion of a reaction site comprising the steps of:
a) selecting a scaffold backbone for attaching structural diversity elements;
b) forming an n × m array of different chemical compounds, wherein each chemical compound comprises the scaffold backbone and at least one structural diversity element;
c) simultaneously screening each compound in the n × m array against the reaction site to determine the chemical compound having the most reactivity to the reaction site;
d) determining the structure of the compound
(n,m) in the array having the greatest reactivity; e) forming a second k × l array comprising the most reactive compound from the n × m array and its isomers, homologs and analogs;
f) simultaneously screening the k × l array of compounds against the reaction site to determine the chemical compound having the greatest reactivity to the reaction site; and g) determining the structure and electrostatic configuration of the compound from the k × l array having the greatest reactivity.
PCT/US1996/001005 1995-01-20 1996-01-19 A method of generating a plurality of chemical compounds in a spatially arranged array WO1996022529A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
PL96327437A PL327437A1 (en) 1995-01-20 1996-01-19 Method of obtaining a plurality of chemical compounds in a three-dimensionally ordered table
NZ301594A NZ301594A (en) 1995-01-20 1996-01-19 Generating a plurality of chemical compounds in a spatially arranged array whereby the scaffold is an aminimide, imidazolone, sulphonylaminimide, and/or phophonylaminimide
JP8522446A JPH11503720A (en) 1995-01-20 1996-01-19 Method for producing multiple chemicals in a spatially arranged array
EP96902775A EP0804726A4 (en) 1995-01-20 1996-01-19 A method of generating a plurality of chemical compounds in a spatially arranged array
AU47059/96A AU719584C (en) 1995-01-20 1996-01-19 A method of generating a plurality of chemical compounds in a spatially arranged array
NO973335A NO973335L (en) 1995-01-20 1997-07-18 Process for the preparation of a plurality of chemical substances in a table arrangement

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/375,838 US5712171A (en) 1995-01-20 1995-01-20 Method of generating a plurality of chemical compounds in a spatially arranged array
US375,838 1995-01-20

Publications (1)

Publication Number Publication Date
WO1996022529A1 true WO1996022529A1 (en) 1996-07-25

Family

ID=23482579

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/001005 WO1996022529A1 (en) 1995-01-20 1996-01-19 A method of generating a plurality of chemical compounds in a spatially arranged array

Country Status (13)

Country Link
US (4) US5712171A (en)
EP (1) EP0804726A4 (en)
JP (1) JPH11503720A (en)
KR (1) KR100414424B1 (en)
AU (1) AU719584C (en)
CA (1) CA2210949A1 (en)
CZ (1) CZ232297A3 (en)
HU (1) HUP9802293A3 (en)
IL (1) IL116838A0 (en)
NO (1) NO973335L (en)
NZ (1) NZ301594A (en)
PL (1) PL327437A1 (en)
WO (1) WO1996022529A1 (en)

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998046551A1 (en) * 1997-04-16 1998-10-22 Arqule, Inc. Synthesis and use of biased arrays
WO1999026901A1 (en) * 1997-11-24 1999-06-03 Biofocus Plc Method of designing chemical substances
WO1999033860A1 (en) * 1997-12-31 1999-07-08 Amersham Pharmacia Biotech Ab Method for binding albumin and means to be used in the method
US5968361A (en) * 1998-02-24 1999-10-19 Arqule, Inc. Rapid method for separation of small molecules using reverse phase high performance liquid chromatography
EP1085943A1 (en) * 1998-05-20 2001-03-28 Selectide Corporation Three-dimensional array of supports for solid-phase parallel synthesis and method of use
US6497820B1 (en) 1998-02-03 2002-12-24 Arqule, Inc. Rapid method for separation of small molecules using reverse phase high performance liquid chromatography
WO2010074783A1 (en) 2008-12-23 2010-07-01 The Trustees Of Columbia University In The City Of New York Phosphodiesterase inhibitors and uses thereof
EP2267029A2 (en) 1999-09-03 2010-12-29 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of inflammatory disease using Cadherin-11 modulating agents
WO2011072243A1 (en) 2009-12-10 2011-06-16 The Trustees Of Columbia University In The City Of New York Histone acetyltransferase activators and uses thereof
WO2012051567A2 (en) 2010-10-15 2012-04-19 The Trustees Of Columbia University In The City Of New York Obesity-related genes and their proteins and uses thereof
WO2012061537A2 (en) 2010-11-02 2012-05-10 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
US8303974B2 (en) 2007-06-11 2012-11-06 Edge Therapeutics, Inc. Drug delivery system for the prevention of cerebral vasospasm
EP2633864A1 (en) 2008-07-25 2013-09-04 The Regents of the University of Colorado Clip inhibitors and methods of modulating immune function
EP2644205A1 (en) 2007-04-12 2013-10-02 The Brigham and Women's Hospital, Inc. Targeting ABCB5 for cancer therapy
WO2013149194A1 (en) 2012-03-29 2013-10-03 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
US8697875B2 (en) 2008-12-23 2014-04-15 The Trustees Of Columbia University In The City Of New York Phosphodiesterase inhibitors and uses thereof
US9198911B2 (en) 2010-11-02 2015-12-01 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
US9364432B2 (en) 2007-06-11 2016-06-14 Edge Therapeutics, Inc. Intraventricular drug delivery system for improving outcome after a brain injury affecting cerebral blood flow
US9399019B2 (en) 2012-05-09 2016-07-26 Evonik Corporation Polymorph compositions, methods of making, and uses thereof
EP3072555A1 (en) 2011-09-02 2016-09-28 The Trustees of Columbia University in the City of New York Mk2/3 inhibitors to treat metabolic disturbances of obesity
US9686971B2 (en) 2006-06-29 2017-06-27 The Trustees Of Columbia University In The City Of New York Methods for testing anti-thrombotic agents
US9771562B2 (en) 2012-11-26 2017-09-26 The Trustees Of Columbia University In The City Of New York Method for culture of human and mouse prostate organoids and uses thereof
US9969677B2 (en) 2010-12-22 2018-05-15 The Trustees Of Columbia University In The City Of New York Histone acetyltransferase modulators and uses thereof
US10092524B2 (en) 2008-06-11 2018-10-09 Edge Therapeutics, Inc. Compositions and their use to treat complications of aneurysmal subarachnoid hemorrhage
US10640457B2 (en) 2009-12-10 2020-05-05 The Trustees Of Columbia University In The City Of New York Histone acetyltransferase activators and uses thereof

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5463564A (en) * 1994-09-16 1995-10-31 3-Dimensional Pharmaceuticals, Inc. System and method of automatically generating chemical compounds with desired properties
AU1582197A (en) 1996-01-22 1997-08-11 Eli Lilly And Company Combinatorial process for preparing substituted indane libraries
US6528324B1 (en) * 1996-03-22 2003-03-04 Ontogen Corporation Apparatus for pre-determined mass sorting of positional-encoded solid phase synthesis supports
AU4153497A (en) * 1996-08-26 1998-03-19 Eli Lilly And Company Combinatorial process for preparing substituted thiophene libraries
US6149869A (en) * 1996-10-23 2000-11-21 Glaxo Wellcome Inc. Chemical synthesizers
US6042789A (en) * 1996-10-23 2000-03-28 Glaxo Group Limited System for parallel synthesis of organic compounds
WO1998020459A1 (en) 1996-11-04 1998-05-14 3-Dimensional Pharmaceuticals, Inc. System, method, and computer program product for the visualization and interactive processing and analysis of chemical data
US6571227B1 (en) 1996-11-04 2003-05-27 3-Dimensional Pharmaceuticals, Inc. Method, system and computer program product for non-linear mapping of multi-dimensional data
US6453246B1 (en) 1996-11-04 2002-09-17 3-Dimensional Pharmaceuticals, Inc. System, method, and computer program product for representing proximity data in a multi-dimensional space
US6054325A (en) * 1996-12-02 2000-04-25 Glaxo Wellcom Inc. Method and apparatus for transferring and combining distinct chemical compositions with reagents
US6083761A (en) * 1996-12-02 2000-07-04 Glaxo Wellcome Inc. Method and apparatus for transferring and combining reagents
JP4704317B2 (en) * 1996-12-26 2011-06-15 株式会社日本触媒 Method for producing resin particles
US5976894A (en) * 1997-04-14 1999-11-02 Pharmacopeia, Inc. Combinatorial amide alcohol libraries
WO1998056028A1 (en) * 1997-06-03 1998-12-10 Arqule, Inc. An automated, high throughput method for screening a plurality of compounds using mass spectrometry
WO1999004778A1 (en) * 1997-07-22 1999-02-04 Eli Lilly And Company Pharmaceutical compounds
WO1999029280A2 (en) * 1997-12-11 1999-06-17 The President & Fellows Of Harvard College Anti-picornaviral ligands via a combinatorial computational and synthetic approach
US6083682A (en) * 1997-12-19 2000-07-04 Glaxo Group Limited System and method for solid-phase parallel synthesis of a combinatorial collection of compounds
US6495539B1 (en) 1998-02-19 2002-12-17 Washington University B-lactam-like chaperone inhibitors
DE19812210C1 (en) 1998-03-19 1999-05-06 Siemens Ag Motor vehicle unauthorised usage prevention device
AU767185B2 (en) 1998-03-23 2003-11-06 President And Fellows Of Harvard College Synthesis of compounds and libraries of compounds
US6541211B1 (en) * 1998-05-20 2003-04-01 Selectide Corporation Apparatus and method for synthesizing combinational libraries
US5993662A (en) * 1998-08-28 1999-11-30 Thetagen, Inc. Method of purifying and identifying a large multiplicity of chemical reaction products simultaneously
US6827979B2 (en) * 1999-01-07 2004-12-07 Northwestern University Methods utilizing scanning probe microscope tips and products therefor or produced thereby
US20020122873A1 (en) * 2000-01-05 2002-09-05 Mirkin Chad A. Nanolithography methods and products therefor and produced thereby
US6635311B1 (en) * 1999-01-07 2003-10-21 Northwestern University Methods utilizing scanning probe microscope tips and products therefor or products thereby
JP4865129B2 (en) * 1999-01-13 2012-02-01 ザ・リサーチ・ファウンデーション・オブ・ステイト・ユニバーシティ・オブ・ニューヨーク Novel method for designing protein kinase inhibitors
US7070936B1 (en) 1999-01-13 2006-07-04 The Research Foundation Of State University Of New York Method for designing protein kinase inhibitors
US6291516B1 (en) 1999-01-13 2001-09-18 Curis, Inc. Regulators of the hedgehog pathway, compositions and uses related thereto
US6500609B1 (en) * 1999-02-11 2002-12-31 Scynexis Chemistry & Automation, Inc. Method and apparatus for synthesizing characterizing and assaying combinatorial libraries
US6355641B1 (en) 1999-03-17 2002-03-12 Syntex (U.S.A.) Llc Oxazolone derivatives and uses thereof
US6824987B1 (en) 1999-05-11 2004-11-30 President And Fellows Of Harvard College Small molecule printing
US7932213B2 (en) * 1999-05-11 2011-04-26 President And Fellows Of Harvard College Small molecule printing
FR2795022A1 (en) * 1999-06-21 2000-12-22 Michelin Soc Tech Assembly has pneumatic tyre whose beads are connected by two deformable adapters to rim no more than half width of fully inflated tyre
US6362342B1 (en) 1999-06-29 2002-03-26 Lion Bioscience Ag Triazole compounds and methods of making same
US6524863B1 (en) 1999-08-04 2003-02-25 Scynexis Chemistry & Automation, Inc. High throughput HPLC method for determining Log P values
US6413431B1 (en) 1999-08-10 2002-07-02 Scynexis Chemistry & Automation, Inc. HPLC method for purifying organic compounds
US6387273B1 (en) 1999-08-27 2002-05-14 Scynexis Chemistry & Automation, Inc. Sample preparation for high throughput purification
US20030044846A1 (en) 2001-04-03 2003-03-06 Gary Eldridge Screening of chemical compounds purified from biological sources
US6585995B1 (en) * 1999-09-21 2003-07-01 Hanson Stephen R Methods and compositions for treating platelet-related disorders
AU1476601A (en) 1999-11-09 2001-06-06 Sri International Array for the high-throughput synthesis, screening and characterization of combinatorial libraries, and methods for making the array
US7033840B1 (en) 1999-11-09 2006-04-25 Sri International Reaction calorimeter and differential scanning calorimeter for the high-throughput synthesis, screening and characterization of combinatorial libraries
JP2003519495A (en) * 2000-01-11 2003-06-24 マキシジェン, インコーポレイテッド Integrated systems and methods for diversity generation and screening
US7416524B1 (en) 2000-02-18 2008-08-26 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. System, method and computer program product for fast and efficient searching of large chemical libraries
US6671627B2 (en) 2000-02-29 2003-12-30 3-D Pharmaceuticals, Inc. Method and computer program product for designing combinatorial arrays
US7039621B2 (en) 2000-03-22 2006-05-02 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. System, method, and computer program product for representing object relationships in a multidimensional space
US6683108B1 (en) 2000-03-30 2004-01-27 Curis, Inc. Agonists of hedgehog signaling pathways and uses related thereto
US7115653B2 (en) 2000-03-30 2006-10-03 Curis, Inc. Small organic molecule regulators of cell proliferation
US6613798B1 (en) 2000-03-30 2003-09-02 Curis, Inc. Small organic molecule regulators of cell proliferation
US8852937B2 (en) * 2000-03-30 2014-10-07 Curis, Inc. Small organic molecule regulators of cell proliferation
US20050070578A1 (en) * 2000-03-30 2005-03-31 Baxter Anthony David Small organic molecule regulators of cell proliferation
AU2001249805A1 (en) 2000-04-03 2001-10-15 3-Dimensional Pharmaceuticals, Inc. Method, system, and computer program product for representing object relationships in a multidimensional space
US6339182B1 (en) 2000-06-20 2002-01-15 Chevron U.S.A. Inc. Separation of olefins from paraffins using ionic liquid solutions
CA2419600A1 (en) * 2000-08-22 2002-02-28 3-Dimensional Pharmaceuticals, Inc. Method, system, and computer program product for determining properties of combinatorial library products from features of library building blocks
WO2002025504A2 (en) * 2000-09-20 2002-03-28 Lobanov Victor S Method, system, and computer program product for encoding and building products of a virtual combinatorial library
US6908732B2 (en) 2000-10-13 2005-06-21 President & Fellows Of Harvard College Compounds and methods for regulating cell differentiation
AU2002239740A1 (en) * 2000-10-20 2002-06-11 Chad A. Mirkin Nanolithography methods and products therefor and produced thereby
WO2002061419A1 (en) * 2001-01-29 2002-08-08 3-Dimensional Pharmaceuticals, Inc. Method, system, and computer program product for analyzing combinatorial libraries
US20020155338A1 (en) * 2001-04-24 2002-10-24 Nitech S. A. Electrochemical cell
CA2462833C (en) * 2001-10-02 2012-07-03 Northwestern University Protein and peptide nanoarrays
US7005445B2 (en) * 2001-10-22 2006-02-28 The Research Foundation Of State University Of New York Protein kinase and phosphatase inhibitors and methods for designing them
JP4623962B2 (en) * 2001-10-22 2011-02-02 ザ・リサーチ・ファウンデーション・オブ・ステイト・ユニバーシティ・オブ・ニューヨーク Protein kinases and phosphatase inhibitors, methods of designing them, and methods of using them
US6846846B2 (en) * 2001-10-23 2005-01-25 The Trustees Of Columbia University In The City Of New York Gentle-acting skin disinfectants
US7361310B1 (en) 2001-11-30 2008-04-22 Northwestern University Direct write nanolithographic deposition of nucleic acids from nanoscopic tips
US20040009495A1 (en) * 2001-12-07 2004-01-15 Whitehead Institute For Biomedical Research Methods and products related to drug screening using gene expression patterns
US20040023248A1 (en) * 2001-12-07 2004-02-05 Whitehead Institiute For Biomedical Research Methods and reagents for improving nucleic acid detection
US6849774B2 (en) * 2001-12-31 2005-02-01 Chevron U.S.A. Inc. Separation of dienes from olefins using ionic liquids
AU2003209054A1 (en) * 2002-02-07 2003-09-02 Discovery Genomics, Inc. Factors for angiogenesis, vasculogenesis, cartilage formation, bone formation and methods of use thereof
WO2003088970A2 (en) 2002-04-22 2003-10-30 Johns Hopkins University School Of Medicine Modulators of hedgehog signaling pathways, compositions and uses related thereto
EP2319523A1 (en) 2002-04-30 2011-05-11 Trustees Of Tufts College Serine protease inhibitors
KR20050026396A (en) * 2002-05-31 2005-03-15 인디언 카운실 오브 애그리컬쳐럴 리서치 Rapid detection of bt-cry toxins
US7108992B2 (en) * 2002-11-27 2006-09-19 St. Jude Children's Research Hospital ATM kinase compositions and methods
JP2008503602A (en) 2004-06-16 2008-02-07 ダウ グローバル テクノロジーズ インコーポレイティド Apparatus and method for Ziegler-Natta research
US7683003B2 (en) 2004-06-16 2010-03-23 Dow Global Technologies, Inc. Method for identifying Ziegler-Natta cocatalysts
CN102321201B (en) 2004-06-16 2013-06-26 陶氏环球技术有限责任公司 Method for selecting polymerization modifiers
WO2006039569A1 (en) * 2004-09-30 2006-04-13 The University Of Chicago Combination therapy of hedgehog inhibitors, radiation and chemotherapeutic agents
CA2608194A1 (en) 2005-05-09 2006-11-16 Hydra Biosciences, Inc. Compounds for modulating trpv3 function
US7333907B2 (en) * 2005-07-29 2008-02-19 Agilent Technologies, Inc. System and methods for characterization of chemical arrays for quality control
EP1945202A2 (en) * 2005-11-11 2008-07-23 Licentia OY Mammalian hedgehog signaling inhiabitors
JP2009522576A (en) * 2006-01-03 2009-06-11 プレジデント アンド フェローズ オブ ハーバード カレッジ Small molecule printing
US7838542B2 (en) * 2006-06-29 2010-11-23 Kinex Pharmaceuticals, Llc Bicyclic compositions and methods for modulating a kinase cascade
US20080103116A1 (en) * 2006-11-01 2008-05-01 Jennings-Spring Barbara L Method of treatment and compositions of D-chiro inositol and phosphates thereof
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
US20090214474A1 (en) * 2006-11-01 2009-08-27 Barbara Brooke Jennings Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
US20080242559A1 (en) * 2007-03-28 2008-10-02 Northwestern University Protein and peptide arrays
JP6151879B2 (en) 2007-08-31 2017-06-21 ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ Stimulation of the WNT pathway in reprogramming somatic cells
WO2009089380A2 (en) * 2008-01-08 2009-07-16 The Trustees Of Columbia University In The City Of New York Methods for p2ry5 mediated regulation of hair growth and mutants thereof
US20110045053A1 (en) * 2009-08-18 2011-02-24 Shen Michael M Isolated population of luminal stem cells that give rise to prostate cancer and methods of using same
WO2013109738A1 (en) 2012-01-17 2013-07-25 The Trustees Of Columbia University In The City Of New York Novel phosphodiesterase inhibitors and uses thereof
WO2015009930A2 (en) 2013-07-17 2015-01-22 The Trustees Of Columbia University In The City Of New York Novel phosphodiesterase inhibitors and uses thereof
US10900030B2 (en) * 2015-04-14 2021-01-26 Illumina, Inc. Structured substrates for improving detection of light emissions and methods relating to the same

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288514A (en) * 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support

Family Cites Families (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1809950U (en) 1959-12-29 1960-04-21 Kabelwerke Reinshagen G M B H INSULATED ELECTRICAL CABLE.
US3410880A (en) * 1963-10-30 1968-11-12 Procter & Gamble N-trialkylammonium imides of higher fatty acids
DE1545810A1 (en) 1965-05-06 1969-12-11 Hoechst Ag Process for the preparation of benzenesulfonylsemicarbazides
US3450673A (en) * 1965-09-07 1969-06-17 Ashland Oil Inc Polyurethane compositions from diaminimides
US3488389A (en) * 1965-09-07 1970-01-06 Ashland Oil Inc Perfluoroimides
NL131743C (en) 1965-12-17
DE1745348A1 (en) * 1967-12-01 1971-09-09 Roehm Gmbh Copolymers containing azlactone groups
US3598790A (en) * 1966-07-01 1971-08-10 Roehm & Haas Gmbh Azlactone copolymers
US3488327A (en) * 1967-06-30 1970-01-06 Roehm & Haas Gmbh Preparation of coating materials
DE1645225C3 (en) * 1966-09-10 1974-08-29 Roehm Gmbh, 6100 Darmstadt Process for the production of graft polymers
DE1618399A1 (en) 1967-04-05 1970-11-05 Hoechst Ag Process for the preparation of N-sulfonyl-N'-alkyl ureas
US3499032A (en) * 1967-04-25 1970-03-03 Ashland Oil Inc Hydroxyl-,mercapto-,and amino-substituted aminimides
US3664990A (en) * 1967-05-05 1972-05-23 Ashland Oil Inc Acrylic aminimides and polymers thereof
US3527802A (en) * 1967-05-05 1970-09-08 Ashland Oil Inc Acrylic aminimides
US3756994A (en) * 1967-08-23 1973-09-04 Ashland Oil Inc Vinyl aromatic aminimides and polymers thereof
US3641145A (en) * 1967-08-23 1972-02-08 Ashland Oil Inc Vinyl aromatic aminimides
US3485806A (en) * 1968-02-07 1969-12-23 Ashland Oil Inc Hydroxy substituted aminimides
US3565868A (en) * 1968-03-19 1971-02-23 Ashland Oil Inc Polymers of unsymmetrical disubstituted hydrazine
US3671473A (en) * 1968-03-19 1972-06-20 Ashland Oil Inc Polymers formed from the reaction of a mixture of a polyepoxide and a polyester and an unsymmetrical disubstituted hydrazine
US3555095A (en) * 1968-03-19 1971-01-12 Ashland Oil Inc Hydroxy aminimines
US3676453A (en) * 1968-11-07 1972-07-11 Merck & Co Inc Oxazole and oxazol-5-one derivatives
US3567725A (en) * 1968-11-20 1971-03-02 Merck & Co Inc Process for preparation of 1h-imidazo-(4,5-b)pyrazin-2-ones
DE1809950A1 (en) 1968-11-20 1970-06-11 Basf Ag Substituted hydrazine derivatives and agents containing them for regulating plant growth
JPS494853B1 (en) * 1969-03-14 1974-02-04
US3706797A (en) * 1969-08-06 1972-12-19 Ashland Oil Inc Bisacyl aminimides
US3706800A (en) * 1970-02-26 1972-12-19 Ashland Oil Inc Process for the preparation of aminimides
DE2009218C3 (en) * 1970-02-27 1980-07-17 Roehm Gmbh, 6100 Darmstadt Process for the bead polymerization of ethylenically unsaturated monomers
US3781319A (en) * 1970-09-28 1973-12-25 Univ Iowa Process for preparing isocyanates
US3811887A (en) * 1970-12-18 1974-05-21 Konishiroku Photo Ind Photographic material comprising bisacylhydrazinium compounds
JPS4843809B1 (en) * 1970-12-18 1973-12-20
US3803220A (en) * 1971-03-02 1974-04-09 Kendall & Co Mono aminimide derivatives of unsaturated dicarboxylic acids
US3893974A (en) * 1971-04-20 1975-07-08 Permachem Asia Co Ltd Epoxy resin compositions containing aminimide compound
US3850969A (en) * 1971-05-28 1974-11-26 Ashland Oil Inc Process for the preparation of hydroxy substituted aminimides
US3715343A (en) * 1971-08-11 1973-02-06 Ashland Oil Inc Polymers of vinyl aminimides
US3963703A (en) * 1971-09-13 1976-06-15 Ashland Oil, Inc. Trialkylammonium -N-[β(1-aziridinyl)] propionoylimines
US3904749A (en) * 1971-10-22 1975-09-09 Ashland Oil Inc Hair setting preparations
US3818065A (en) * 1971-12-22 1974-06-18 Basf Ag Production of aminoacid precursors
US3828007A (en) * 1972-02-18 1974-08-06 Ashland Oil Inc Process of reacting isocyanate or isothiocyanate and compositions therefor
US3728387A (en) * 1972-03-17 1973-04-17 Ashland Oil Inc Acrylamide of methacrylamide monomer with n-substituted amininmide residues
US4070348A (en) * 1973-07-25 1978-01-24 Rohm Gmbh Water-swellable, bead copolymer
US3969298A (en) * 1973-08-24 1976-07-13 The Kendall Company Selected lipophilic aminimides and polymers derived therefrom useful for making stable emulsions
US3983166A (en) * 1974-03-18 1976-09-28 The Kendall Company Monomeric emulsion stabilizers
US3934035A (en) * 1974-04-29 1976-01-20 Michigan State University Certain aminimides used to control bacteria and fungi
US3934031A (en) * 1974-04-29 1976-01-20 Michigan State University Certain aminimides used to control bacteria and fungi
US3934029A (en) * 1974-04-29 1976-01-20 Michigan State University Certain aminimides used to control bacteria and fungi
US3946131A (en) * 1974-05-06 1976-03-23 Owens-Corning Fiberglas Corporation Glass fibers coated with silicon containing aminimide compounds
US3898087A (en) * 1974-06-14 1975-08-05 Ball Corp Photopolymerizable compositions containing aminimides
US3963776A (en) * 1974-06-24 1976-06-15 E. I. Du Pont De Nemours And Company Amine fluoroacylimide surfactants
US3925284A (en) * 1974-06-24 1975-12-09 Upjohn Co Polyisocyanate-based foam process using aminimides as catalyst
US3968065A (en) * 1974-12-30 1976-07-06 The B. F. Goodrich Company Vulcanizable polymer blends of a halogen-containing polymer and a carboxyl-containing polymer
US4080206A (en) * 1974-12-30 1978-03-21 Polaroid Corporation Photographic processing composition containing polyvinyl aminimide
US3985807A (en) * 1975-03-31 1976-10-12 Ashland Oil, Inc. Alkoxy derivatives of hydroxy aminimides
US4005055A (en) * 1975-05-22 1977-01-25 Skeist Laboratories, Incorporated Anaerobic aminimide curing compositions
US4016340A (en) * 1975-08-07 1977-04-05 Polaroid Corporation Hydroxyl-containing polymers having aminimide groups attached thereto through an ether linkage
US4046658A (en) * 1975-08-15 1977-09-06 General Motors Corporation Process for electrocoating aminimide containing compositions
US4022623A (en) * 1975-10-28 1977-05-10 Polaroid Corporation Photosensitive emulsion containing polyvinyl aminimide polymers
US4189481A (en) * 1975-11-18 1980-02-19 Michigan State University Antimicrobial compositions
US4217364A (en) * 1975-11-18 1980-08-12 Michigan State University Antimicrobial compositions
DE2608482C2 (en) * 1976-03-02 1978-03-30 Hoechst Ag, 6000 Frankfurt Process for coloring water-insoluble, thermoplastic polymers and polycondensates in bulk
US4067830A (en) * 1976-03-29 1978-01-10 Ashland Oil, Inc. Catalytic trimerization of polyisocyanates
US4162355A (en) * 1976-06-30 1979-07-24 Board Of Regents, For And On Behalf Of The University Of Florida Copolymers of (a) aminimides and (b) vinyl pendant primary halomethy monomers useful for affinity chromatography
US4260705A (en) * 1976-06-30 1981-04-07 Board Of Regents, For And On Behalf Of The University Of Florida Addition copolymers of aminimides useful for affinity chromatography
US4212905A (en) * 1976-06-30 1980-07-15 Board of Reagents, for and on behalf of the University of Florida Method of coating supports using addition copolymers of aminimides
US4213860A (en) * 1976-06-30 1980-07-22 Board of Regents, State of Florida for and on behalf of the University of Florida Affinity chromatography and substrate useful therefor
US4102916A (en) * 1976-12-02 1978-07-25 Ciba-Geigy Corporation Perfluoroalkylthioaminimide derivatives
US4078901A (en) * 1976-12-20 1978-03-14 Texaco Inc. Detergent fuel composition
US4140680A (en) * 1976-12-22 1979-02-20 Polaroid Corporation 2-Acrylamido-2-methylpropane sulfonic acid vinyl aminimide/copolymer
US4280008A (en) * 1976-12-24 1981-07-21 Basf Aktiengesellschaft Chirally substituted 2-imidazolin-5-ones
FR2381813A1 (en) * 1977-02-24 1978-09-22 Oreal FOAMING COMPOSITION FOR PRESSURIZED CONTAINER OF THE "AEROSOL BOMBE" TYPE
US4304705A (en) * 1980-01-02 1981-12-08 Minnesota Mining And Manufacturing Company Radiation-curable polymers containing pendant unsaturated peptide groups derived from azlactone polymers
US4378411A (en) * 1980-01-02 1983-03-29 Minnesota Mining And Manufacturing Company Radiation-curable polymers
US4424272A (en) * 1981-08-03 1984-01-03 Polaroid Corporation Temporary polymeric mordants and elements containing same
US4777276A (en) * 1981-10-29 1988-10-11 Minnesota Mining And Manufacturing Company Acrylamidoacylated oligomers
US4485236A (en) * 1982-09-27 1984-11-27 Minnesota Mining And Manufacturing Company Azlactone-functional compounds
US4451619A (en) * 1982-09-30 1984-05-29 Minnesota Mining And Manufacturing Company Method of hydrophilizing or hydrophobizing polymers
FR2540870A1 (en) * 1983-02-15 1984-08-17 Provesan Sa NOVEL DERIVATIVES OF N-IMINOPYRIDINIUM BETA, THEIR PREPARATION AND THEIR APPLICATION AS MEDICAMENTS
US4548981A (en) * 1983-07-01 1985-10-22 Polaroid Corporation Compositions and articles containing polymeric vinyl aromatic aminimides
US4695608A (en) * 1984-03-29 1987-09-22 Minnesota Mining And Manufacturing Company Continuous process for making polymers having pendant azlactone or macromolecular moieties
US4617253A (en) * 1984-06-06 1986-10-14 Polaroid Corporation Polymeric pyridinium ylides and products prepared from same
US4667012A (en) 1984-12-14 1987-05-19 Minnesota Mining And Manufacturing Company Imidazolinone-containing polymer and copolymer
US4631211A (en) * 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
US4624995A (en) * 1985-04-09 1986-11-25 Minnesota Mining And Manufacturing Company Triazolinethione-containing polymer
US4740568A (en) * 1985-04-09 1988-04-26 Minnesota Mining And Manufacturing Company Triazolinethione-containing polymer
CA1325222C (en) 1985-08-23 1993-12-14 Lederle (Japan), Ltd. Process for producing 4-biphenylylacetic acid
US4645711A (en) * 1985-08-26 1987-02-24 Minnesota Mining And Manufacturing Company Removable pressure-sensitive adhesive tape
US4705824A (en) * 1986-02-14 1987-11-10 W. R. Grace & Co. Poly(5-imidazolone) and process therefor
US4777217A (en) * 1987-02-26 1988-10-11 Minnesota Mining And Manufacturing Company Methacrylamide functional polymers and method
US4871824A (en) * 1987-03-13 1989-10-03 Minnesota Mining And Manufacturing Company Variably crosslinked polymeric supports
US4737560A (en) * 1987-03-13 1988-04-12 Minnesota Mining And Manufacturing Company Polymer beads
US4816554A (en) * 1987-05-27 1989-03-28 Minnesota Mining And Manufacturing Company Poly(amido methyl-benzazole)
US5300425A (en) 1987-10-13 1994-04-05 Terrapin Technologies, Inc. Method to produce immunodiagnostic reagents
US4898923A (en) * 1987-11-30 1990-02-06 Minnesota Mining And Manufacturing Company Polypyridinium copolymer
US4841021A (en) * 1987-11-30 1989-06-20 Minnesota Mining And Manufacturing Company Polypyridinium
GB8803416D0 (en) * 1988-02-15 1988-03-16 Minnesota Mining & Mfg Polymeric polymethine dyes & optical data storage media containing same
US4852969A (en) * 1988-03-17 1989-08-01 Minnesota Mining And Manufacturing Company Silyl 2-amidoacetate and silyl 3-amidopropionate compositions and optical fiber made therefrom
US4874822A (en) * 1988-04-07 1989-10-17 Minnesota Mining And Manufacturing Company Process for the acrylamidoacylation of alcohols
US5225533A (en) 1988-05-02 1993-07-06 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
US5010175A (en) 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE3831717A1 (en) * 1988-09-17 1990-03-22 Basf Ag METHOD FOR PRODUCING DIPEPTIDES WITH N-TERMINAL NON-PROTEINOGENIC AMINO ACIDS
DE3831716A1 (en) 1988-09-17 1990-03-22 Basf Ag METHOD FOR PRODUCING DIPEPTIDES WITH C-TERMINALS NON-PROTEINOGENIC AMINO ACIDS
US5049656A (en) 1988-12-21 1991-09-17 Board Of Regents Of The University Of Nebraska Sequential peptide and oligonucleotide syntheses using immunoaffinity techniques
US5053454A (en) 1989-02-15 1991-10-01 Sri International Multiple polymer synthesizer
US5013795A (en) * 1989-04-10 1991-05-07 Minnesota Mining And Manufacturing Company Azlactone graft copolymers
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5424186A (en) 1989-06-07 1995-06-13 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
US5185102A (en) 1989-06-08 1993-02-09 Minnesota Mining And Manufacturing Company Polymeric charge transfer complexes for nonlinear optical applications
US4981933A (en) * 1989-06-23 1991-01-01 Polaroid Corporation Azlactone copolymers
US5075352A (en) * 1989-08-15 1991-12-24 Minnesota Mining And Manufacturing Company Stabilized polymeric dispersions
US5147957A (en) * 1989-09-22 1992-09-15 Minnesota Mining And Manufacturing Company Hydrosilated azlactone functional silicon containing compounds and derivatives thereof
US5157108A (en) 1989-12-12 1992-10-20 Minnesota Mining And Manufacturing Company Thermally sensitive linkages
US5066559A (en) * 1990-01-22 1991-11-19 Minnesota Mining And Manufacturing Company Liquid electrophotographic toner
US5149806A (en) 1990-03-28 1992-09-22 Minnesota Mining And Manufacturing Company Azlactone michael adducts
US5039813A (en) * 1990-06-29 1991-08-13 Polaroid Corporation 2-(4-alkenylphenyl)-5-oxazolones and polymers thereof
US5094766A (en) * 1990-07-02 1992-03-10 Texaco Inc. Dispersant-antioxidant viscosity index improver
US5175081A (en) 1990-08-31 1992-12-29 Minnesota Mining And Manufacturing Company Post-processsing stabilization of photothermographic emulsions
US5194623A (en) 1990-08-31 1993-03-16 Minnesota Mining And Manufacturing Company Azlactone based photographic reagents
US5091489A (en) * 1990-10-23 1992-02-25 Minnesota Mining And Manufacturing Company Oligo (2-alkenyl azlactones)
US5081197A (en) * 1990-10-23 1992-01-14 Minnesota Mining And Manufacturing Company Oligo(2-alkenyl azlactones)
US5200471A (en) 1990-11-05 1993-04-06 Minnesota Mining And Manufacturing Company Biomolecules covalently immobilized with a high bound specific biological activity and method of preparing same
US5449754A (en) 1991-08-07 1995-09-12 H & N Instruments, Inc. Generation of combinatorial libraries
US5359115A (en) 1992-03-26 1994-10-25 Affymax Technologies, N.V. Methods for the synthesis of phosphonate esters
US5324483B1 (en) 1992-10-08 1996-09-24 Warner Lambert Co Apparatus for multiple simultaneous synthesis
US5367053A (en) 1993-05-19 1994-11-22 Houghten Pharmaceuticals, Inc. Opioid peptide inhibitors
US5463564A (en) 1994-09-16 1995-10-31 3-Dimensional Pharmaceuticals, Inc. System and method of automatically generating chemical compounds with desired properties

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288514A (en) * 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JUNG G., BECK-SICKINGER A. G.: "MULTIPLE PEPTIDE SYNTHESIS METHODS AND THEIR APPLICATIONS.", ANGEWANDTE CHEMIE INTERNATIONAL EDITION, WILEY - V C H VERLAG GMBH & CO. KGAA, DE, vol. 31., no. 04., 1 April 1992 (1992-04-01), DE, pages 367 - 383., XP000325208, ISSN: 1433-7851, DOI: 10.1002/anie.199203673 *
See also references of EP0804726A4 *

Cited By (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998046551A1 (en) * 1997-04-16 1998-10-22 Arqule, Inc. Synthesis and use of biased arrays
WO1999026901A1 (en) * 1997-11-24 1999-06-03 Biofocus Plc Method of designing chemical substances
WO1999033860A1 (en) * 1997-12-31 1999-07-08 Amersham Pharmacia Biotech Ab Method for binding albumin and means to be used in the method
US6497820B1 (en) 1998-02-03 2002-12-24 Arqule, Inc. Rapid method for separation of small molecules using reverse phase high performance liquid chromatography
US5968361A (en) * 1998-02-24 1999-10-19 Arqule, Inc. Rapid method for separation of small molecules using reverse phase high performance liquid chromatography
EP1085943A4 (en) * 1998-05-20 2006-08-02 Selectide Corp Three-dimensional array of supports for solid-phase parallel synthesis and method of use
EP1085943A1 (en) * 1998-05-20 2001-03-28 Selectide Corporation Three-dimensional array of supports for solid-phase parallel synthesis and method of use
EP2267029A2 (en) 1999-09-03 2010-12-29 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of inflammatory disease using Cadherin-11 modulating agents
US9686971B2 (en) 2006-06-29 2017-06-27 The Trustees Of Columbia University In The City Of New York Methods for testing anti-thrombotic agents
EP3431103A1 (en) 2007-04-12 2019-01-23 The Brigham and Women's Hospital, Inc. Targeting abcb5 for cancer therapy
EP2644205A1 (en) 2007-04-12 2013-10-02 The Brigham and Women's Hospital, Inc. Targeting ABCB5 for cancer therapy
US9364432B2 (en) 2007-06-11 2016-06-14 Edge Therapeutics, Inc. Intraventricular drug delivery system for improving outcome after a brain injury affecting cerebral blood flow
US8303974B2 (en) 2007-06-11 2012-11-06 Edge Therapeutics, Inc. Drug delivery system for the prevention of cerebral vasospasm
US10092524B2 (en) 2008-06-11 2018-10-09 Edge Therapeutics, Inc. Compositions and their use to treat complications of aneurysmal subarachnoid hemorrhage
EP2633864A1 (en) 2008-07-25 2013-09-04 The Regents of the University of Colorado Clip inhibitors and methods of modulating immune function
US9974782B2 (en) 2008-12-23 2018-05-22 The Trustees Of Columbia University In The City Of New York Phosphodiesterase inhibitors and uses thereof
US8697875B2 (en) 2008-12-23 2014-04-15 The Trustees Of Columbia University In The City Of New York Phosphodiesterase inhibitors and uses thereof
US9422242B2 (en) 2008-12-23 2016-08-23 The Trustees Of Columbia University In The City Of New York Phosphodiesterase inhibitors and uses thereof
WO2010074783A1 (en) 2008-12-23 2010-07-01 The Trustees Of Columbia University In The City Of New York Phosphodiesterase inhibitors and uses thereof
US11034647B2 (en) 2009-12-10 2021-06-15 The Trustees Of Columbia University In The City Of New York Histone acetyltransferase activators and uses thereof
US10640457B2 (en) 2009-12-10 2020-05-05 The Trustees Of Columbia University In The City Of New York Histone acetyltransferase activators and uses thereof
EP3632901A1 (en) 2009-12-10 2020-04-08 The Trustees of Columbia University in the City of New York Histone acetyltransferase activators and uses thereof
WO2011072243A1 (en) 2009-12-10 2011-06-16 The Trustees Of Columbia University In The City Of New York Histone acetyltransferase activators and uses thereof
US10912816B2 (en) 2010-10-15 2021-02-09 The Trustees Of Columbia University In The City Of New York Obesity-related genes and their proteins and uses thereof
WO2012051567A2 (en) 2010-10-15 2012-04-19 The Trustees Of Columbia University In The City Of New York Obesity-related genes and their proteins and uses thereof
US9895301B2 (en) 2010-11-02 2018-02-20 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
US10265258B2 (en) 2010-11-02 2019-04-23 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
US11806555B2 (en) 2010-11-02 2023-11-07 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
US9763866B2 (en) 2010-11-02 2017-09-19 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
US11298570B2 (en) 2010-11-02 2022-04-12 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
US9737469B2 (en) 2010-11-02 2017-08-22 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
US9730877B2 (en) 2010-11-02 2017-08-15 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
WO2012061537A2 (en) 2010-11-02 2012-05-10 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
US9198911B2 (en) 2010-11-02 2015-12-01 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
US10994157B2 (en) 2010-11-02 2021-05-04 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
US9969677B2 (en) 2010-12-22 2018-05-15 The Trustees Of Columbia University In The City Of New York Histone acetyltransferase modulators and uses thereof
EP3072555A1 (en) 2011-09-02 2016-09-28 The Trustees of Columbia University in the City of New York Mk2/3 inhibitors to treat metabolic disturbances of obesity
US9771430B2 (en) 2011-09-02 2017-09-26 The Trustees Of Columbia University In The City Of New York Method of treating a metabolic disorder induced by obesity in a subject in need thereof by administering MK2/3 inhibitors
WO2013149194A1 (en) 2012-03-29 2013-10-03 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
EP3459565A1 (en) 2012-03-29 2019-03-27 The Trustees of Columbia University in the City of New York Methods for treating hair loss disorders
US9399019B2 (en) 2012-05-09 2016-07-26 Evonik Corporation Polymorph compositions, methods of making, and uses thereof
US9771562B2 (en) 2012-11-26 2017-09-26 The Trustees Of Columbia University In The City Of New York Method for culture of human and mouse prostate organoids and uses thereof

Also Published As

Publication number Publication date
JPH11503720A (en) 1999-03-30
NO973335D0 (en) 1997-07-18
US5712171A (en) 1998-01-27
IL116838A0 (en) 1996-07-23
PL327437A1 (en) 1998-12-07
US5736412A (en) 1998-04-07
AU719584C (en) 2001-07-26
HUP9802293A2 (en) 1999-02-01
EP0804726A4 (en) 2004-07-07
AU719584B2 (en) 2000-05-11
EP0804726A1 (en) 1997-11-05
KR19980703097A (en) 1998-10-15
AU4705996A (en) 1996-08-07
CA2210949A1 (en) 1996-07-25
NO973335L (en) 1997-08-21
US5962736A (en) 1999-10-05
HUP9802293A3 (en) 1999-03-29
NZ301594A (en) 1999-01-28
US6878557B1 (en) 2005-04-12
CZ232297A3 (en) 1998-06-17
KR100414424B1 (en) 2004-07-07

Similar Documents

Publication Publication Date Title
AU719584C (en) A method of generating a plurality of chemical compounds in a spatially arranged array
US5807754A (en) Combinatorial synthesis and high-throughput screening of a Rev-inhibiting arylidenediamide array
US5646285A (en) Combinatorial non-peptide libraries
Still Discovery of sequence-selective peptide binding by synthetic receptors using encoded combinatorial libraries
US5891737A (en) Combinatorial non-peptide libraries
US6265228B1 (en) Process for preparing combinatorial amide alcohol libraries
JPH09507487A (en) Systematic modular production of amine-imide and oxazolone-based molecules with selected properties
JP2002520008A (en) Use of an improved universal library of peptide nucleic acids to optimize DNA sequence hybridization
WO1995002566A1 (en) Synthesis of combinatorial arrays of organic compounds through the use of multiple component combinatorial array syntheses
WO1997042216A1 (en) Auto-deconvoluting combinatorial libraries
US5981467A (en) Aminimide-containing molecules and materials as molecular recognition agents
AU783339B2 (en) Computer-assisted formulation of culture media
Metz et al. Small molecule screening on chemical microarrays
Simon et al. Using peptoid libraries [oligo N-substituted glycines] for drug discovery
US20120129730A1 (en) Generation of compound libraries utilizing molecular imprints including a double or anti-idiotypic approach
Ambre et al. Combinatorial Chemistry: Role in Lead Discovery
Gund et al. Applying informatics systems to high-throughput screening and analysis
WO1996040732A1 (en) Combinatorial non-peptide libraries
NANDAN et al. PREMLATA K. AMBRE, ANISH N. GOMATAM
Wilson Introduction to combinatorial libraries: concepts and terms
WO2009067657A2 (en) Methods of identifying molecular function
Khanuja et al. REVIEW ON COMBINATORIAL CHEMISTRY
Kumar et al. An overview on Combinatorial Chemistry
Palzkill Protein Arrays and Protein Chips
Germeroth et al. Combinatorial Organic Compound Libraries on Continuous Surfaces: Towards Chemical Chips

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AU AZ BB BG BR BY CA CN CZ EE FI GE HU IS JP KG KP KR KZ LK LR LS LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK TJ TM TR TT UA UZ VN AZ BY KG KZ RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2210949

Country of ref document: CA

Kind code of ref document: A

Ref document number: 2210949

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PV1997-2322

Country of ref document: CZ

Ref document number: 1019970704928

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 1996 522446

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1996902775

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 301594

Country of ref document: NZ

WWP Wipo information: published in national office

Ref document number: 1996902775

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV1997-2322

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1019970704928

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 1019970704928

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: PV1997-2322

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1996902775

Country of ref document: EP